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Meta-analysis is an essential tool that facilitates clinicians, medical experts and decision
makers to cope with the information overload in the public and healthcare sectors. The
publication of meta-analyses is increasing rapidly every day with less or more of method-
ological rigour. Clinicians and medical experts depend wholeheartedly on the results and
conclusions obtained from analyzing meta-analysis in order to assess the clinical eectiveness
of healthcare intervention on a daily basis. Meta-analysis provides a specic estimate of a
relationship which may also indicate if there is any need for further research.
But the foundational problem of performing the clinically powerful meta-analysis is the
guideline for how similar the studies must be in order to meet the inclusion criteria of the
meta-analysis and the reliability of its conclusions [1]. When there are discrepancies in the
studies being combined and patient populations being studied, meta-analysis may provide
results that are wrong. These may mislead potential users of meta-analysis to give wrong
prescriptions to their patients.
One requirement is to prepare a validated and reliable checklist that can assess the
quality of meta-analysis in terms of reporting, methodology, science and most especially, the
actual statistical analysis. Literature review reveals that existing checklists mainly focus on
other aspects of quality with little or no attention to the quality of statistical methodology.
Consequently, this thesis attempts to cover this gap.
OBJECTIVE- To construct an appropriate validated quality instrument. Use the instru-
ment to assess the quality of selected meta-analyses in terms of actual statistical analysis. To
assess accuracy and consistency of reported estimates using Lee's [2] methods for checking
errors in reported relative risks, odds ratios and condence intervals.STUDIES - Eligible articles (Meta-analysis of randomised controlled trials) identied in
the Cochrane database, Web of Knowledge and Medline databases were used in this project.
Eligibility criteria include studies published in English language, as a full report between
the periods of 2000-2008, have a comprehensive search strategy and have clear methods of
selecting studies for inclusion and performed statistical analysis.
We developed a checklist that measures the quality of meta-analysis in terms of actual
statistical analysis and used the instrument to assess papers published in both Cochrane and
Non-Cochrane reviews.
RESULTS: A sample size of 100 papers was obtained using an estimated maximum
error bound of 0.1. Studies were allocated equally between Cochrane and Non-Cochrane
publications and selections were made from electronic databases. Records of meta-analysis
of randomised contolled trials published in English, full text and journal articles between
the periods of 2000 - 2008 show that there were 515 results out of 5821 records of meta-
analysis published in Cochrane library, 507 out of 1434 records and 130 out of 135 records
of meta-analysis published in Web of Knowledge and Medline respectively. Simple random
sampling, implemented in R statistical package, was used to select random sample of studies
from each database. 83 out of the 100 selected studies met the inclusion criteria - 42 studies
from Cochrane reviews and 41 from Non-Cochrane reviews.
Reporting and methodology quality are high in the two databases. However, in terms
of statistical analysis, both databases are unlikely to explicitly state the design of individ-
ual studies combined in the meta- analysis. The Cochrane review is more likely to con-
tact authors of published studies than their Paper-base counterparts. Cochrane reviews are
less likely also, to use OQAQ(Overview Quality Assessment Questionnaire) and QUOROM
(Quality of Reporting of Meta-analyses)in asssessment of validity of studies than paper re-
views.
There was no double counting of some aspects of studies identied among Paper-base
iiJournals while we discovered four studies in Cochrane reviews that double counted the control
arms.
However, there was no simple double counting of studies found in both Cochrane and
Non-Cochrane reviews.
Lee's checks were performed on the twenty selected studies to verify errors on reported
odd ratios, relative risks and condence intervals. Some studies included in the meta-analysis
reported zero events either in the treatment or control groups or both which led to a disparity
between our calculated results and the estimates reported by the authors. The addition of
a continuity correction factor of 0.5 to each cell of the studies with zero events took care of
the disparities. Mabinary sas macro designed by Weir and Senn [3] was also used to assess
and check the validity of reported odd ratios, relative risks and condence intervals on both
reviews. The results obtained using the macro are consistent with the original reported
results in most of the studies.
Studies reporting relative risks in both Paper-Base Journals and Cochrane reviews are
more likely to disagree with the Lee's requirement on minimum subject size and number of
diseased subjects in either exposure groups given the CI, than those reporting odd ratios.
These studies also have large outcomes. This seems to suggest that Lee's checks are not
reliable for studies reporting relative risks, especially when outcomes are relatively large.
CONCLUSION: Cochrane Handbooks and scales relating to specic interventions were
mostly used to assess quality of studies in Cochrane reviews. Results showed no statistically
signicant dierence between the reporting and methodological quality of Cochrane and
non-Cochrane publications. More improvement is needed in the reportage of the design
of included studies in both Cochrane and non-Cochrane reviews. This will help establish
if the combined studies and the statistical method used in combining them are compatible.
However, double counting of some aspects of studies was found in some meta-analysis selected
from Cochrane reviews. Analysis suggests that studies reporting odd ratios are likely to be
iiiconsistent with Lee's checks than those reporting relative risks. We also showed that Peter
Lee's checks involving totals cannot be relied on to assess the quality of studies reporting
relative risks.
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1Chapter 1
INTRODUCTION
According to Kulik et al [4], meta-analysis has a long past and a short history. The history
of meta-analysis began in 1976 when Glass[5] rst used the term in his presidential address
to the American Educational Research Association to describe the statistical analysis of
ndings from a large number of independent studies. Glass described meta-analysis as the
\analysis of analyses". He went on to dene Meta-analysis more formally as the statistical
analysis of a large collection of analysis results from individual studies for the purpose of
integrating the ndings [5]. But the roots of meta-analysis go as far back as 1904 when Karl
Pearson used formal techniques to combine data from dierent studies when examining the
preventive eect of serum inoculations against enteric fever [6].
Fisher was one of the rst to devise a means for transforming and combining P values. He
noticed that the natural logarithm of a value given by P of a test multiplied by -2 is exactly
distributed as a chi square with two degrees of freedom and that the sum of independent
chi-square is also distributed as chi-square [7]. Cochran's method of integrating treatment
eects was developed to deal with results from a planned series of studies [8]. According to
Rosenthal [9], meta-analysis is the use of statistical techniques either to combine or compare
either eect size measures for probability levels from two or more studies. Glass [5] also
2outlined the following summary of steps which an analyst should undertake, (a) the meta-
analyst uses objective methods to nd studies for a review (b) Describe the features of studies
in quantitative or quasi-quantitative terms (c) Expresses treatment eects of all studies or
a common scale of eect size, and (d) uses statistical techniques to relate study features to
study outcomes.
Hedge's contribution to meta-analysis was his demonstration that the eect size statistics
usually calculated for meta-analyses were biased estimators of an underlying population eect
[10].
Chalmers [11] devised a strategy for combining clinical trials to summarize ndings and
published the rst meta-analysis in medicine. This earned him the 1982 annual research
award of the Evaluation Research Society for his accomplishment.
The term 'meta-analysis' has been adopted within other disciplines and has proved par-
ticularly popular in clinical research [12]. Over the past one and half decades, the number
of meta-analyses published annually has increased greatly[13]. Several hundred are now
published each year [14].
According to the Cochrane Collaboration [15],\It is an independent, not-for-prot organ-
isation established in 1993, named in honour of Professor Archibald Leman Cochrane (1909
- 1988), a British epidemiologist who advocated the use of randomised controlled trials as a
means of reliably informing healthcare practice. It is also an international network of people
assisting healthcare providers, decision makers, policy makers, patients, their advocates and
carers make well-informed decisions about human health care by preparing, updating and pro-
moting the accessibility of Cochrane Reviews. Cochrane reviews are scientic investigation
that synthesize results of multiple primary investigations using approaches that limit bias and
random error. These approaches include a comprehensive search of all potentially relevant
studies and the use of explicit, reproducible criteria in the selection of studies for review.
Cochrane reviews are published in Cochrane library".
3The Cochrane library is an independent high quality evidence base for health-care decision
making. It is an online collection of databases that brings together in one place rigorous and
up-to-date research on the eectiveness of healthcare treatments and interventions, as well as
methodology and diagnostic tests [16]. Hence, the rich storehouse of Cochrane Collaboration
will provide us with limitless information on the quality of statistical content of meta-analysis
published over the years [17].
In order to obtain the actual number of Meta-analysis published over the years, we made
a simple search through the Web of Knowledge (ISI) by typing the words *Meta-analysis
* OR *Meta analysis * OR *Metaanalysis *.The search yielded a total of 71,901 records.
Analysing this number of publications by year, choosing a selected eld (Publication year)
to analyze up to 100000 records with a minimum record count of 10 from the set display
options in the ISI Web of Knowledge Database, gave the result represented in the Figure1.1.
Figure 1.1 shows the trend of publications of meta-analysis between 1944 and 2008. The
rst four decades (1944-1987) witnessed a slow but steady increase in the number of Meta{
analyses published. However, the last two decades (1988-2008) saw an astronomical rise in
the number of Meta-analyses published in various journals per year. A closer scrutiny of the
graph show that in 1944 only 6 Meta-analyses were published compared to 10,350 published
in 2008.
Cochrane library conrmed the increasing diusion of meta-analysis with theoretical
and methodological advances as well as from empirical research [18].A recent check in the
Cochrane database of systematic reviews indicate that the total number of meta-analyses
published was nearly 6000.
Citations and uses of meta-analyses in health-related literature have been rising very
rapidly over the past decade and can oer a rational and helpful way of dealing with a
number of practical diculties that beset anyone trying to make sense of the eectiveness
of research [18]. However, \it seems that Meta-analysis has not always been embraced
4Figure 1.1: Trend in the publication of Meta-analysis
5with enthusiasm within the Pharmaceutical industries"[19]. The International Conference
Harmony(ICH) E9 [20] while acknowledging the usefulness of meta-analysis as a means
of summarising overall drug ecacy also warns that conrmation of ecacy solely from
meta-analysis will not usually be accepted as a substitute for conrmation of ecacy from
individual trials. This is because the magnitude of the treatment eect is likely to be
an important factor in regulatory decision-making. If the treatment eect is smaller than
anticipated, then statistical signicance may not be reached in the individual trials even if the
statistical signicance is reached in the meta-analysis. Therefore, it is considered insucient
for approval when the magnitude of treatment eect may not be clinically signicant [21].
1.0.1 Three basic types of Meta-analysis
According to Senn [19], meta-analysis can be grouped broadly into three types depending
on the nature of the data being summarized:
 Type A: the outcome measure is the same in all trials being analyzed, the analyst has
access to all original data and chooses to base the analysis on these data.
 Type B: the outcome measure is the same in all trials being analyzed but the analyst
uses summaries from each trialqw as the basis of analysis, the original data are not
available.
 Type C: dierent outcomes have been measured in dierent trials and analysis has to
proceed using unit-free summaries.
1.0.2 Conducting Meta-analysis
DeCoster [22] outlined the following steps for the conduct of meta-analysis.
 Dene the theoretical relationship of interest
6 Location of studies-: meta-analysis requires a comprehensive search strategy
 Selection of studies based on inclusion criteria stated, selection of quality of studies
and selection of specic studies based on the specic subjects.
 Examine the distribution of eect sizes and analyse the impact of moderating variables
 Interpret and report the results
1.1 BACKGROUND
Meta-analyses have been suggested to be the utmost outline of evidence available to clinicians
to guide clinical practice in critical care[23]. Given this strategic position, the quality of
every Meta-analysis is expected to be of the highest standard [24]. Consequently, several
authors have described the sources of bias and errors during the design, conduct, and analysis
of meta-analyses, [25],[26],[27] and at least one instrument has been developed according to
conventional methodological standards to assess the methodological rigour, reporting quality
or scientic quality of review articles [28],[29].
Some of the popular instruments include:
OQAQ (Overview Quality Assessment Questionnaire) this is a validated instrument con-
sisting of 10-items checklist, used to assess the scientic quality of an overview research.
Mulrow [30] was rst to draw attention to the poor scientic quality of healthcare review
articles. Later, Oxman and Guyatt[31] published a guideline to help readers assess reviews
in health care. Many authors have used this tool to evaluate and assess the validity of
reporting and methodology, Example, Boluyt et al [32] used this tool to evaluate clinical,
methodological and reporting aspects of systematic reviews on acute Asthma management
in children and found that the methodological quality of both Cochran and Journal reviews
seem good, with Cochran reviews being more rigorous. Bereza et al [33] considered this
7instrument less than fair-to-good on their ndings for assessing the reporting and scientic
quality of meta-analyses of randomised controlled trials of treatments for Anxiety Disorders.
Empirical evidence suggested that inadequate methodological reporting correlates with bias
in estimation of treatment eects.
QUOROM (Quality Of Reporting Of Meta-analyses) consists of an 18-items checklist.
A conference was convened to address standards for improving the quality of reporting of
meta-analysis of randomised controlled trials, this resulted in the QUOROM statement, a
checklist and a ow diagram for reporting on meta-analysis and systematic Reviews [34] .
Example, Junehua et al [35] assessed the methodology and reporting quality of systematic
reviews/meta-analyses of traditional Chinese Medicine, published in paper-based journals in
china and concluded that the methodology and reporting quality are poor in both systematic
reviews/meta-analysis of TCM. Schulz [36] stated that faulty reporting appears to portray
faulty methods.
However, all these instruments failed to assess the quality of the statistical methods
employed in the meta-analysis. It is a well known fact that the use of a wrong statistical
method on the best data yields results that are at best misleading [37],[38]. The use of
meta-analysis has been criticised on statistical grounds in the past,[39], [40]. Indeed, the
potential for the misuse of meta-analysis has been well recognized even by those who have
done the most to develop it as a methodology [41];[4].
Assessing the quality of meta-analyses in terms of actual statistical analysis is important
and relatively new. Quality gives an estimate indication of the likelihood that the results
are valid estimates of the truth and the major problems with the implementation of meta-
analyses have been common [42], [43] ,[44],[45] . There has been a wide variety of these,
including failure of investigators performing the meta-analysis to understand the basic is-
sues, carelessness in abstracting,summarizing and concluding appropriate papers, failure to
consider important covariates, bias on the part of the meta-analyst, and perhaps most often,
8overstatements of the strength and precision of the results [46]. It is not unusual to nd
that two or more meta-analyses done at about the same time by investigators with the same
access to the literature, reach incompatible or even contradictory conclusions [47], [48].
The dilemma of missing studies in meta-analysis has received much attention and less
attention has been paid to the more serious problem of overstating the evidence [49]. These
potential problems with meta-analysis concerning missing studies were due to publication
bias, that is, studies with unfavourable outcomes tend to be suppressed , data missing at the
study level, example, investigators may not report estimates of treatment eect size and/or
study-level covariates in a publication [50] and also data missing at the individual patient
level, such as non-response [51].
1.1.1 Problem of overstating the precision of results from meta-
analysis
Senn [52] outlined ways in which precision could be overstated in meta-analyses as follows
 Simple double counting of studies
 Double counting of some aspects of studies,
 Accepting implausible claims for the precision of studies
 Imputing data
 Spurious precision of individual trials
 Inappropriate pooling of treatments,
 Numerical slips and poor reporting
91.2 SOURCES OF DATA
It was decided that studies should be selected from the Cochrane collaboration and non-
Cochrane databases of systematic reviews using an appropriate sampling plan.
1.3 OBJECTIVES OF THE STUDY
 To evaluate the criteria currently being used in assessing the scientic quality of re-
search reviews.
 To establish an appropriate quality instrument.
 To develop a pilot study to check the instrument's practicability
 To assess the quality of meta-analyses in term of actual statistical analysis.
 To compare the quality of Cochrane and non-Cochrane meta-analyses
 To establish the validity and reliability of the instrument.
 To summarise the results and draw suitable inferences
 To check errors in reported estimates(Relative Risks, Odds Ratios and Condence
Intervals) using Peter Lee's method.
10Chapter 2
LITERATURE REVIEW
Our research interest was to develop a validated, comprehensive and reliable checklist that
can assess the quality of meta-analysis in terms of actual statistical analysis. Numerous
standardized checklists had been developed by various clinicians, editors, research groups
and authors to measure and improve research quality on external and internal validity of
clinical studies and meta-analyses, to assess the quality of reports of randomised controlled
trials, to assess the methodological quality and scientic quality of included trials with
particular emphasis on selection, performance, attribution, critical appraisal and detection
of bias in a research medical literature. Little consideration has been given to the statistical
quality of meta-analysis.
A checklist is a comprehensive list of an important or relevant action or step to ensure
consistency or completeness in carrying out a task and it is formatted as list with small
checkboxes down the left hand side of the page and use checkmarks or 'yes' or 'no' or
'unsure' to denote if an item on the checklist has been completed satisfactorily or if the
characteristic is present [53].
112.1 USES AND APPLICATIONS OF CHECKLIST
A checklist can be applied in medical practice to ensure that clinical practice guidelines are
carried out accordingly.
Wikipedia[53] listed the use and applications of checklist as follows:
 It can be used as a human factor aid in aviation safety to ensure that long lists of an
items are not forgotten.
 A checklist can be used as a job-aid to help in evaluation and in decision-making.
 It is used to determine the value of process, procedure, decision, solution and outcome
of research literature.
 It can be modied to check the level of quality, priority, importance and condition of
each item in the list.
2.2 BENEFITS OF CHECKLIST
\Advantages of Checklist"as given by the Mindre Solutions [54] on Checklist Driven Testing
- An Overview are listed below:
 A checklist draws on a range of issues that help in deciding where to concentrate eort
 A checklist is a predened guideline to quality, which is created over time and is an
investment both of time and energy.
 A checklist helps guide developers in reducing errors and preventing errors in assess-
ment
 Checklists work as a reminder to testers. The essential tests, which testers tend to
forget , can be entered to checklists to ensure that these tests get executed
122.3 REVIEW OF CHECKLISTS
Early attempt at developing checklists for the evaluation of dierent aspects of quality of
meta-analysis of randomised control trials can be traced to the early 1960s. It does seem
that the rst documented checklist is a procedure outlined by Mahon and Daniel [55] in
1964 to assess the accuracy of reports of drug trials. They were the rst to identify a lack
of rigour [56],[57], [58].
Mulrow(1987) [30] used a checklist on \Policy Research Incorporated Literature Review
Validation Procedures Manual"[59],[60],[61], developed around 1979. She assessed fty re-
views published during June 1985 to 1986 in four major medical journals. Her results signied
that the present medical reviews do not regularly apply scientic methods to identify, as-
sess and synthesize information, then She drew attention to the poor scientic quality of
healthcare review articles.
Sacks et al evaluated the quality of 86 meta-analyses of reports of randomized controlled
trials in English-language literature, using a scoring method that considered 23 items in six
major areas which includes - study design, combinability, bias control, statistical analysis,
sensitivity analysis, and application of results. They concluded that an urgent need exists
for improved techniques in literature searching, quality evaluation of trials, and synthesizing
of the results [62].
2.3.1 (OQAQ)-Overviews of Quality of Assessment Questionnaire
(1991)
Following the above assertions, Oxman and Guyatt(1991) [31] published guidelines to help
readers assess the quality of reviews in health care and it was used to prepare valid checklist
that measures the quality of research overviews. The instrument consists of 9-items checklist
and is titled \Overviews of Quality of Assessment Questionnaire"(OQAQ) as itemised below.
13The authors believed that this instrument can be productively used by the readers and editors
of clinical trials to identify scientically sound overviews and thus judge the condence that
should be placed in their conclusions [31].
Criteria for assessing the scientic quality of research overviews by Oxman and Guy-
att(1991) [31] are
 Were the search methods reported?
 Was the search comprehensive?
 Were the inclusion criteria reported?
 Was selection bias avoided?
 Were the validity criteria reported?
 Was validity assessed appropriately?
 Were the methods used to combine studies reported?
 Were the ndings combined appropriately?
 Were the conclusions supported by the reported data?
 What was the overall scientic quality of the overview?
2.3.2 Blind Assessment of the Quality of Trials Reports(1996)
From other perspective, the designed instrument failed to measure in detail the statistical
quality of the overviews. Jadad et al(1996) [63] suggested that the quality of clinical trials
should be assessed by blinded raters to limit the risk of introducing bias in meta-analyses and
systematic reviews, and into the peer-reviews process. They assembled a multidisciplinary
14panel of judges with an interest in pain research who also had experience in the develop-
ment of instruments [63]. They generated items to be considered in the instrument termed
Jadads'scale for quality of randomised controlled trials around 1996. This instrument (listed
below) is used to assess the quality of clinical reports. Fisher et al [64] stated that results
suggested that blinded reviewers may provide less biased reviews and unblinded reviewers
may be aected by various type of bias.
The designed instrument by Jadad et al(1996) [63] are
 Was the study described as randomized?
 Was the study described as double-blind?
 Was there a description of withdrawals and drop outs?
 Were the objectives of the study dened?
 Were the outcome measures dened clearly?
 Was there an explicit description of the inclusion and exclusion criteria?
 Was the sample size justied (e.g., power calculation)?
 Was there a clear description of the interventions?
 Was there at least one control (comparison) group?
 Was the method used to assess adverse eects described?
 Were the methods of statistical analysis described?
2.3.3 (QUOROM)-QUality Of Reporting Of Meta-analysis of ran-
domised controlled trials (1999)
-
15In 1996, Authors with dierent backgrounds summoned a conference in order to address
issues on present reporting standard of meta-analysis and systematic reviews and need for
improvement. The conference resulted in the production of an instrument termed Quality
Of Reporting Of Meta-analysis (QUOROM) which consists of an 18-items checklist. The
checklist put through the best way to present the abstract, introduction, methods, result
and discussion. The checklist was published in 1999 by Moher et al [65] .
Criteria for improving the quality of reporting by Moher et al(1999) [65] are Title
Abstract
 Objectives
 Data sources
 Reviews methods
 Result
 Conclusion
Introduction
Methods
 Searching
 Selection
 Validity assessment
 Data abstraction
 Study characteristics
 Quantitative data synthesis
Results
16 Trial ow
 Study characteristics
 Quantitative data synthesis
discussion
2.3.4 (MOOSE)-Meta-Analysis of Observational Studies in Epi-
demiology(2000)
Blettner et al [66] were concerned about inherent biases in the original studies. Similarly, the
intense diversity of study designs and populations in epidemiology makes the interpretation of
simple summaries problematic at best. Consequently, methodologic and reporting issues,such
as publication bias, could have an impact when combining results of observational studies
[67],[68]. In order to address this challenge, a workshop was convened in 1997 and guideline
regarding reporting of Meta-analysis Of Observational Study in Epidemiology (MOOSE) was
established to help understand and measure sources of dierences in results across studies
[69].
A proposed Reporting Checklist of observational studies(MOOSE) by Stroup et al(2000)
[67] Reporting of Background
 Hypothesis denition, description of study outcomes,
 Study population and designs used.
Reporting of search strategy
 of searchers, search strategy,
 Databases and registries searched
Reporting of methods
17 Description of relevance of studies, Rationale for the selection and coding of data,
 Documentation of how data were classied and coded,
 Assessment of study quality, provision of appropriate tables and graphics
Reporting of results
 Graphic summarizing individual study estimates and overall estimate,
 Table giving descriptive information for each study included,
 indication of statistical uncertainty of ndings
Reporting of discussions
 Quantitative assessment of bias, justication for exclusion,
 Generation of the conclusions, Guidelines for future research,
 Disclosure of funding source
2.3.5 (CONSORT)-CONsolidated Standard Of Reporting Trials(2001)
The quality of reporting is very important in the medical literature reviews as it provides the
clinicians, experts in medical elds complete and valuable information and guideline to their
daily clinical practice. When there is little or no detailed information in literature reviews,
researchers and potential users would lack knowledge and revelation of fundamental content
of the reviews and the current clinical issues that would be of help in healthcare services and
assessment of the primary studies will be dicult.
Moher et al[65] assert that a lack of suciently reported randomization has been associ-
ated with bias in evaluating the eectiveness of interventions. To assess the strengths and
limitations of randomised controlled trials, readers need and deserve to know the quality of
its methodology.
18Given this limitation on quality of reporting in clinical trials, experts comprising of
medical journal editors, clinical trialists, epidemiologists and methodologists organised a
workshop in 1993 with the aim of developing new instrument that can assess the quality of
reporting on randomised controlled trials . This workshop gave birth to a checklist in 1996.
But still, considerable evidence revealed that only one item in the checklist addressed the
reporting of safety and suggests that reporting on harm-related issues needs improvement.
In 1999, another meeting was held in order to revise and modify the original CONSORT
checklist with intention to standardize, improve and publish reporting of randomised con-
trolled trials and it was actualized in 2001. It consists of a 22-item checklist. The Table
below shows the revised checklist.
Revised Checklist for CONSORT (CONsolidated Standard Of Reporting Trials) by Moher
et al[65]
Paper Section and Topic Title and abstract Introduction
 Background
Methods
 Participants
 Interventions.
 Objectives
 outcome
 Sample size
Randomization
 Sequence generalization
 Allocation concealment
19 Implementation
 Blinding (masking)
 Statistical methods
Results
 Participant ow
 Recruitment
 Baseline data
 Numbers analyzed
 Outcome and estimation
 Ancillary analyses
 Adverse events
Discussion
 Interpretation
 Generalizability
 Overall evidence
2.3.6 (REMARK)-REporting recommendations for tumor MARKer
prognostic studies(2005)
This was a case study of research reports on tumour makers in oncology where several studies
of the same or related makers produced inconsistent conclusions or stand in direct contradic-
tion to the promising results [70]. Attempts have been made to identify reasons why multiple
20studies of the same makers can yield dierent conclusions. Diversity of methodological prob-
lems have been cited to solve this dierences but the reports obtained from study of tumour
makers were not carried out in a rigorous manner and the published articles usually lack
necessary information that can be of help for adequate assessment of study quality . The
rst international conference meeting on Cancer diagnostics was held in 2000 and there was
a recommendation on development of guidelines for the reporting of tumour makers in order
to encourage transparency and complete reporting so that important information should
be available for clinicians and other potential users [71]. This led to the production of the
REMARK checklist given below.
Reporting recommendations for Tumor Maker prognostic studies (REMARK) by Mc-
Shane et al [70]
INTRODUCTION
MATERIALS AND METHODS
 Patients
 Specimen characteristics
 Assay methods
 Study design
 Statistical analysis methods
RESULTS
 Data
 Analysis and presentation
.
DISCUSSION
212.3.7 STARLITE (Sampling strategy,Type of study,Approaches,Range
of years,Limits,Inclusion and exclusions,Terms used,Electronic
sources)(2006)
The use of checklists make it easier for readers to assess the quality of reviews and for
researcher to replicate their methods[72]. These checklists were developed to improve the
quality of reporting, methodological quality and scientic quality of quantitative systematic
reviews, but Booth [73] stated that no standard have been published for reporting literature
searches, the systematic reviews of qualitative research are limited by poor quality of report-
ing of search method and that the criteria for reporting literature search must acknowledge
the demands of both qualitative and quantitative systematic reviews.
They designed structure for reporting the quality of literature searches based on the em-
pirical ndings from their reviews which conveyed using the mnemonic STARLITE (Stan-
dards for Reporting Literature searches).
Representing the elements of STARLITE by Booth (2006) [73]
Element
 S: Sampling strategy
 T: Type of Studies
 A: Approaches
 R: Range of years (start date-end date)
 L: Limits
 I: Inclusion and exclusions
 T: terms Used
 E: Electronic sources
222.3.8 (AMSTAR)Assessment of Multiple Systematic Reviews(2007)
This instrument was developed from the combination of items drawn from two available
checklists- constructed by Oxman et al [74] and Sacks et al[62]. Validated checklist was
developed to measure the methodological quality of systematic reviews. Again, more item
were added in the checklist to determine if the language restriction and publication bias
were applied in selecting studies for systematic reviews [75]. The checklist was designed with
31-item assessment tools. The Table shows the checklist.
AMSTAR was developed by Shea et al
 Was an 'a priori' design provided?
 Was there duplicate study selection and data extraction?
 Was a comprehensive literature search performed?
 Was the status of publication(i.e, grey literature) used as an inclusion criteria?
 Was a list of studies (included and extracted) provided?
 Were the characteristics of the included studies provided?
 Was the scientic quality of included studies assessed and documented?
 Was the scientic quality of the included studies used appropriately in formulating
conclusions?
 were the methods used to combine the ndings of studies appropriate?
 Was the likelihood of publication bias assessed?
 Was the conict of interest stated?
232.3.9 The PRISMA Checklist(2009)
Moher et al who developed The QUOROM statement (Quality Of Reporting Of Meta-
analyses), which focused on the reporting of meta-analyses of randomised controlled trials
was revised, expanded and renamed (PRISMA) \Preferred Reporting Items for Systematic
reviews and Meta-Analyses"in 2009. The aims- to address numerous conceptual and practical
advances in the science of systematic reviews and used as a basis for reporting systematic
reviews of other types of research, especially evaluations of interventions [76]. It consists of
a 27-items checklist. The table below shows the checklist of items included when reporting
meta-analysis or systematic reviews.
The PRISMA Statement developed by Moher et al [76].
Section/topic
TITLE
 Title
ABSTRACT
 Structure summary
INTRODUCTION
 Rationale
 Objectives
METHODS
 Protocol and registration
 Eligibility criteria
 Information sources
 Search
24 Study selection
 Data collection process
 Data items
 Risk of bias in individual studies
 Summary measures
 Synthesis of results
 Risk of bias across studies
 Additional analyses
RESULTS
 Study selection
 Study characteristics
 Risk of bias within studies
 Results of individual studies
 Syntheses of results
 Risk of bias across studies
 Additional analyses
DISCUSSION
 Summary of evidence
 Limitations
25 Conclusions
FUNDING
 Funding
In healthcare systems, there is an increase in health care decisions made on research-base
evidence rather than clinical experience and expert opinions. Meta-analyses were formulated
to represent the rigorous procedure of compiling scientic research evidence to solve problems
concerning healthcare issues on treatment of patients, its interventions and remedy to the
services. However, clinicians and medical experts need to select and read medical literature
reviews of related topic under study in order to be abreast and up-to-date with health care
issues. The review articles under study are being published continuously at high rate. Meta-
analyses and systematic reviews attempt to minimize confounding bias by comprehensive
and reproducibility of search for, article selection for review, and methodological quality.
Criteria were outlined as a guideline and were used to prepare a checklist that can be
used to evacuate all the factors aecting selection and inclusion of studies in meta-analysis.
There are about 25 checklists developed so far from authors of dierent background of
meta-analyses to tackle the problems of poor face validity of study quality. They organised
and convened workshops, conferences and meetings at dierence places to suggest, recom-
mend and propose a validated instruments that can measure the trials' quality based on
meta-analysis, systematic reviews and clinical studies
From literature reviews of nine validated checklists listed above, we discovered that most
checklists were only focused on methodological quality, reporting quality, scientic quality
and inherent bias as criteria for quality assessment in meta-analysis and clinical study. Less
emphasis was placed on statistical methodological quality. Given these facts, we propose to
design and develop a checklist that can assess the quality of meta-analysis in terms of actual
statistical analysis.
262.3.10 The summary of historical checklist
It appears that Mahon and Daniel [55] were the rst to notify that there was a lack of
rigour during literature search in clinical trials. In 1964, they developed a checklist as a
guide to obtaining accurate reports. Between the year 1985/86, Mulrow [30] and Sack et al
[62] commented during their reviews on medical research that there was inconsistency in the
use of scientic method to assess healthcare information. This alertness of poor scientic
methods drew attention of Oxman and Guyatt[31] in 1989 and led to publication of a checklist
(OQAQ) that measures scientic quality of reviews in 1991. Jadad et al(1996)[63] suggested
that there might be a potential risk of bias in meta-analysis when using this checklist without
blinding the raters. Consequently, they introduced their own checklist (Blind Assessment of
the Quality of Trials Reports). Moher et al (1999)[65] had noticed that the present standard
of reporting of meta-analysis of randomised controlled trials was not sucient and that it
needs improvement. They developed checklist called QUOROM .
Blettner et al (2000)[66] were much concerned on the methodological issues related to
meta-analysis such as publication bias and thus they developed guideline (MOOSE). Moher
et al (2001) [65] designed checklist (CONsolidated Standard Of Reporting Trials) to examine
the quality of reporting in randomised controlled trials. There was a report that multiple
studies of the same markers gave dierent conclusions as a result of lack of necessary informa-
tion or not carried out in a rigorous manner. In order to encourage transparency, McShane
et al (2005) [70] designed a checklist, REMARK, to serve as a guideline for the reporting
tumour markers. Booth et al (2006)[73] complained that the present checklists failed to
highlight the criteria / standard for reporting literature search of qualitative and quantita-
tive systematic reviews and they proposed a framework based on the experimental ndings
from the reviews (STARLITE). Oxman et al [74] and Sack et (2007) [75] were apprehensive
that language restriction and publication bias might be a potential risk that will aect the
assessment of the methodological quality of systematic reviews and thereby designed a vali-
27dated checklist (AMSTAR). Finally, as a result of continuous insucient quality of reporting
in the present checklist, QUOROM statement was revised and renamed PRISMA by Moher
et al (2009) [76] in order to addressed more the various formations and practical advances
in the science of systematic reviews and also used as a base for reporting of evaluations of
interventions.
28Chapter 3
DEVELOPMENT OF CHECKLIST
We developed a new checklist to assess the quality of meta-analysis in terms of actual statis-
tical analysis. The current checklists do not alert users of potential problems and rarely have
any item about the statistical analysis. Our checklist consists of 21 items and was designed
to assess the methodological quality, reporting quality and statistical quality of studies. A
pilot study was also carried out to evaluate the eectiveness of the new checklist using some
randomly selected studies.
We articulated the following checklist for the assessment of quality. Item 1 to item 8
were obtained from Oxman et al(1996)[31]
1. Is the objective/aim/hypothesis of the study clearly described?
2. Are the main outcomes to be measured clearly described in the introduction or methods
section?
3. Were comprehensive search methods used to locate relevant studies?
4. Was the validity of the primary studies assessed?
5. Were the inclusion criteria reported?
296. Were explicit methods used to determine which articles to include in the review?
7. Was bias in the selection of studies avoided?
8. Were the criteria used for assessing the validity of the included studies reported?
9. Are the statistical methods used in analysing the data specied in detail?
10. Are the statistical methods appropriate?
11. Are assumptions underlying the statistical tools met by the data?
12. Is the statistical method used in combining studies in harmony with the design of the
clinical trials?
13. Do studies being combined have adequate information to merit inclusion in meta-
analysis?
14. Is the measure of precision available (or can it be derived) for each study being com-
bined?
15. Is there double-counting of studies?
16. Are studies being combined compatible?
17. Are appropriate weights used in combining studies?
18. Is the Statistical software used in obtaining the results stated?
19. Are the actual probability values reported?
20. Are conclusions based on hypothesis test valid?
21. Can results be reproduced by an independent checker
30In order to assess the workability of the instrument, we need to select some studies from
published sources. To do this, we rst determine our population of interest and dene the
sampling plan and inclusion criteria. Cochrane and non-Cochrane publications published
between 2000 and 2008 on meta-analysis of RCTs were chosen as the populations to be
investigated. We have outlined below our inclusion criteria and sampling procedure.
3.1 INCLUSION CRITERIA
All meta-analyses of randomised controlled trials published from 2000 to 2008 in each
database. Also, Meta-analysis of RCT's published in full text, in English language and
journal article were included. Studies that preformed a comprehensive search of literature,
and clearly explain the statistical methods used. Studies published in Cochrane database of
systematic reviews, Medline and Web of knowledge database that state the characteristics of
included studies. We excluded observational, cohort and case control studies, meta-analysis
of discriminant capacity trials and studies without statistical analysis.
3.2 ESTIMATION OF SAMPLE SIZE
Our interest is on published articles on meta-analysis of randomised controlled trials con-
tained in the Cochrane database of systematic reviews and paper-base journal databases
published between the period of 2000 and 2008. The rst approach is to establish a sample
size that would guarantee adequate error bounds on estimates of proportions obtained from
samples.
The variance of a proportion attains its maximum when p = 0:5. A conservative approach
is to choose the value of n that will guarantee a suciently narrow error bound for the worst
case (p = 0:5).
31On the other hand one has to consider resource constraints. From the pilot survey we
conducted, about 25 papers could be reviewed per week. On average, it may be possible
to assess about 100 papers in a month. Using this number of samples and the proportion
of publications on meta-analysis from the database p = 0:5, the estimated maximum error
bound is about 0.1.
3.3 SAMPLING PLAN
A check on Cochrane database of systematic reviews, web of knowledge and Medline database
of reviews indicate valid number of publications on meta-analyses between the period of 2000
- 2008. We estimated the sample size to be 100 and allocated 50 papers each to Cochrane and
non-Cochrane database (Web of Knowledge and Medline). The 50 papers allocated to the
non-Cochrane database were distributed proportionally to Web of Knowledge and Medline.
3.3.1 Sampling Frame
All eligible studies published in the Cochrane and non-Cochrane libraries on Meta-analysis
of Randomised Controlled Trials between 2000 and 2008 constitute our target population.
A search through the Electronic databases showed that in Cochrane library, there are
4646 results out of 5821 records for Meta-analysis of Randomised Controlled Trials published
between 2000 and 2008 in Cochrane database of systematic reviews. In non-Cochrane library
there are 1434 results of Meta-analysis of RCT's published in database of Web of knowledge
of Figure 1.1 and 135 results of Meta-analysis of RCT's published in database of Medline
within the same period.
323.3.2 Studies meeting Inclusion Criteria
Further comprehensive search was performed for studies on meta-analysis of Randomised
Controlled Trials published in ENGLISH, FULL TEXT and are JOURNAL articles. Search
results were obtained directly from electronic database of Cochrane, Web of Knowledge and
Medline as shown below.
Cochrane Library There were 515 results out of 5821 records for: \Meta-analysis of
Randomised Controlled Trials* OR Metaanalysis of randomised controlled trials* or Meta
analysis of Randomised Controlled Trials* published in English language and full text and
journal article, from 2000 to 2008 in Cochrane Database of Systematic Reviews"
`
Web of Knowledge and Medline There were 507 and 130 results of Meta-analysis
of Randomised Controlled Trials OR Metaanalysis of Randomised Controlled Trials OR
Meta analysis of Randomised Controlled Trials published in full text, in English and journal
published in Web of Knowledge and Medline databases respectively, Timespan = 2000-2008
3.3.3 Choice of database
The choice of Cochrane Library and Medline databases for this research is informed by the
fact that they contain the most up to date, peer reviewed, high quality, and strong scientic-
based journals published in meta-analysis. Medline is a powerful tool to eciently access
the voluminous amount of medical literature. It is a premier database of biomedicine and
health sciences [77]. The use of Web of Knowledge is to enable us have access to scientic
journals published elsewhere outside the Cochrane library and Medline. Web of Knowledge
provides easy links to full texts and has analysis tool that helps to rene searches by authors,
publication year, source title or subject category [77]. It makes it easy to spot developing
trends which give insight into tracing the history of particular eld of study.
333.3.4 Sample Size Allocation
Basically, the estimated sample size of 100 were equally distributed among Cochrane and
non-Cochrane (Medline and Web of Knowledge) libraries. Fifty papers were allocated to
Cochrane database and the other fty papers were allocated proportionally to Medline and
Web of Knowledge.
The proportional allocation for the sample size of 50 papers between Web of Knowledge
and Medline is calculated below as;
Web of Knowledge (WOK) = 507 results of meta-analysis of RCT's meeting the inclusion
criteria.
Medline = 130 results of meta-analysis of RCT's meeting the inclusion criteria
These give a total of 507 + 130 = 637
To obtain the actual sample size for WOK and Medline, the proportion of each is calcu-
lated as shown below
WOK = 507=637  50 = 40
Medline = 130=637  50 = 10
This shows that the sample size of 40 papers is allocated to Web of Knowledge database
and sample size of 10 papers to Medline database. From each database, random sample of
publications were selected that met the inclusion criteria until the sample size is attained.
Fig 3.1 reveals the owchart of the procedure used to arrive at selected studies from
Cochrane and Non-Cochrane database. 17 studies were excluded as they did not meet the
inclusion criteria. We included 42 eligible studies obtained from Cochrane database, 31 and
10 eligible studies obtained from Web of knowledge and Medline respectively.
34Figure 3.1: Flowchart of studies: Search for Meta-analysis and reasons for inclusion.
353.3.5 Sample selection from Databases
Studies were searched using eld labels. Example, \Metaanalysis of RCTs* OR \Meta-
analysis of RCTs* OR \Meta analysis of RCTs* published in English, full text and Journal
articles. The search was restricted to Cochrane database of Systematic Reviews and date
ranging from 2000 to 2008, likewise in Web of Knowledge and Medline. The actual number
of search results appeared along with the long list of published studies consisting of record
title, name of the author(s), year of publication, source, volume, issue and pages. Search
results obtained from the Cochrane Library website were subsequently assigned with serial
numbers. Then, using the random numbers generated in R package in the previous section,
we selected the study that has the corresponding number. We then downloaded and saved
it for further study.
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APPLICATION OF THE NEW
CHECKLIST TO SELECTED
STUDIES
4.1 PILOT STUDY
To assess the quality of meta-analysis in terms of actual statistical analysis and methodology
quality, a pilot study was rst conducted to verify the completeness and reliability of the
instrument designed in the previous chapter. Studies were retrieved from the Cochrane
database and Paper-based journals (Web of Knowledge and Medline) published between
2000 and 2008. We assessed 17 papers from a group of 50 papers randomly selected from
the Cochrane library, 12 trials from group of 40 studies randomly selected from Web of
Knowledge and 10 studies from Medline using our newly developed 21-item checklist. This
enabled us to assess the completeness, adequacy and the ability of the instrument to capture
the salient information needed to eectively assess studies. This led to a slight modication
of the instrument.
374.2 MODIFICATION OF CHECKLIST
The initial 21-item checklist was subjected to a pilot study. This exposed the need to examine
more thoroughly the content of the checklist and also concentrate more on the statistical
quality aspects of the reviews. Consequently, we made some modications on the checklist
by generating more items and expressed them in more explicit form. We added four extra
items (as listed below) and deleted item 10-(Are the statistical methods appropriate?) from
the checklist. We now have an instrument with 24 items, (as shown in Figure 4.1), that has
the potential to assess the statistical and overall quality of studies.
The four items added to the checklist is listed below.
 Was the aim of using the statistical method stated?
 Was the use of statistical methods justied?
 Were the study design of individual trials stated in meta-analysis? E.g Parallel,
crossover, factorial etc.
 Are there double counting of some aspects of studies?
4.3 RELIABILITY CHECK
We propose to evaluate the eectiveness of the modied instrument and use it to measure
the quality of meta-analysis in terms of actual statistical analysis. A re-assessment of the
statistical and methodological quality of all the reviewed study showed that it was easier,
faster and less time consuming using the modied checklist.
The reliability of the 24-item checklist was established by assessing all the studies in two
separate times. Results obtained in the two assessments were identical and highly consistent.
Cronback's alpha was used to check the internal consistency of the checklist. This yielded
38Figure 4.1: Modied Checklist
39very high correlation value of 0.92. This gave us the condence to apply our checklist to
some selected studies.
4.4 ASSESSMENT OF STUDIES
All the 83 studies were assessed using the modied checklist. Needed information were then
extracted and analysed.
4.4.1 Data Extraction
Data for analysis were extracted by assessing the quality of studies in the Cochrane and
Journal reviews using the modied checklist. The studies from Non-Cochrane library (Web
of Knowledge and Medline) were merged together to give a single group.
From each trial, data were extracted on:
 Meta-analysis of randomised controlled trials
 Full detail of the background of study
 The comprehensive search strategy
 Stating the explicit methods used to identify trials for reviews
 The statistical method used, the aim of using it and its justication
 The reporting of statistical software and actual Probability value
 Whether studies and some aspects of studies were double counted.
 Avoidance of Selection bias and publication bias
 The type of designs used for each study and how they were combined
40 Validation of primary study assessment
 Whether inclusion criteria were stated and method of determining included articles
We used the statistical package SAS 9.1 version and R package to perform the Fisher
Exact Test in order to determine if there are non-random associations between the databases
[78]. Some sample sizes were small with expected cell frequencies less than ve in some cases.
We judged that it was unsafe to rely on the chi-squared test and used Fisher's exact test
instead. Two-sided Fisher's exact test was used to analyse the responses to the 24 items
in the checklist as shown in Table 4.2. We computed the proportions that describe the
statistical quality between Cochrane and Paper-base journals. Each item is regarded as
being statistically signicant if the P-value < 0:05. There is no adjustment for multiple
testing therefore results should be interpreted cautiously in the light of this.
An example of the SAS procedure used in carrying out the Fisher Exact test is given
below: A=31, B=23 C=11 D=18 data Qua;
input $ paper $ objective count;
datalines;
cc yes 31
cc no 11
jn yes 23
jn no 18
run;
procfreqdata = Qua;
tables paper*objective / sher;
weight count;
title 'quality of meta-analysis in terms of actual statistical analysis';
run;
41paper objective
Frequency
Percent
Row Pct
Col Pct no yes Total
Cochran 11 31 42
13.25 37.35 50.60
26.19 73.81
37.93 57.41
Journal 18 23 41
21.69 27.71 49.40
43.90 56.10
62.07 42.59
Total 29 54 83
34.94 65.06 100.00
Table 4.1: Fisher's Exact Test
Quality of meta-analysis in terms of actual statistical analysis
The FREQ Procedure
Table of paper by objective
Left-sided Pr = 0:0716,Right-sided Pr = 0:9731, Table Probability (P) = 0:0448, Two-
sided Pr P = 0.1102, Sample Size = 83
Example of R procedure in sher exact test is
database =matrix (c(42,41,0,0),nr=2,dimnames=list(database=c(\cochrane",\journal"),
outcomes=c(\yes",\no"))) sher.test(database)
Fisher's Exact Test for Count Data data: database
p-value = 1
alternative hypothesis: true odds ratio is not equal to 1
95 percent condence interval:
42All CC Paper P-values
The numbers of studies reviewed reviews Reviews Reviews P<0.05
(n = 83) (n = 42) (n = 41)
1 Objective/aim/hypothesis clearly described? 83 42(100%) 41(100%) 1.0
2 Main outcomes clearly described? 83 42(100%) 41 (100%) 1.0
3 Comprehensive search methods used 83 42(100%) 41 (100%) 1.0
4 Validity of the primary studies assessed? 79 42(100%) 37 (90%) 0.055
5 Inclusion criteria reported? 80 42(100%) 38 (93%) 0.12
6 Explicit methods used to determine articles? 79 42(100%) 39 (95%) 0.24
7 Authors of unpublished data contacted? 54 31(74%) 23 (56%) 0.11
8 Bias in the selection of studies avoided? 80 42(100%) 38 (93%) 0.12
9 Criteria for validity assessment reported? 11 1(2.4%) 10 (24%) 0.003
10 Statistical methods used specied? 82 42(100%) 40 (98%) 0.31
11 Aim of using the statistical method stated? 76 38(90%) 37 (90%) 1.0
12 Use of the statistical method justied? 66 34(81%) 32 (78%) 0.89
13 Design of individual trials stated ? 20 13(31%) 7 (17%) 0.2
14 Studies being combined compatible? 22 12(29%) 10 (24%) 0.8
15 Statistical method agree with the study design? 19 12(29%) 7 (17%) 0.3
16 Studies combined have adequate information ? 76 39(93%) 37(90%) 0.71
17 Measure of precision available? 81 41(98%) 40 (98%) 1.0
18 Is there double counting of studies? 0 0 0 1.0
19 Double counting of some aspects of studies? 4 4(10%) 0 (0) 0.24
20 Appropriate weights used in combining studies? 72 39(93%) 33 (80%) 0.12
21 Software used in obtaining the results stated? 58 31(74%) 27 (66%) 0.48
22 Are the actual probability values reported? 76 40(95%) 36 (88%) 0.27
23 valid conclusions based on hypothesis test? 83 42(100%) 41 (100%) 1.0
24 Results reproducible by independent checker? 78 40 (95%) 38 (93%) 0.68
Table 4.2: Checklists for measuring Quality of Meta-analysis in terms of actual Statistical
Analysis
0 Inf
sample estimates:
odds ratio = 0
43Studies Cochrane Journal
1 - 5 9 8
6 - 10 9 18
11 - 15 7 4
16 - 20 4 3
21 - 25 4 2
26 - 30 5 1
31 - 35 2 1
36 - 40 1 0
41 - 45 0 2
46 - 50 1 0
51+ 0 2
TOTAL 42 41
Table 4.3: Number of Trials in each meta-analysis
4.5 RESULTS
4.5.1 Methodological Characteristics
The number of authors involved in conducting meta-analysis of randomised controlled trials
ranged from 2 to 21. However, the number of trials in each meta-analysis included in the
reviews varied from 2 to 52. Most of the reviews included were meta-analysis on randomised
controlled trial. We evaluated the number of included trials and authors of meta-analysis
obtained from the Cochrane and Journal database using R package to plot Stem and Leaf
. We also represent the number of trial and authors of Cochrane and Paper-base Journal
reviews in a frequency table as shown in Tables 4.3 and Table 4.4.
4.5.2 Stem and leaf plot
According to Weisstein[79], a stem and leaf plot is a diagram that summaries the data while
maintaining the individual data point . It is used to show the shape and distribution of
numbers. Stem is the digit in the tens place and leaf is the number in the ones place.
The basic command use in R is
44Authors Cochrane Journal
1 - 3 23 13
4 - 6 15 20
7 - 9 3 4
10 - 12 1 0
13 - 15 0 1
16 - 18 0 2
19 - 21 0 1
TOTAL 42 41
Table 4.4: Number of Authors
stem(Journal.Author, scale=2)
stem(Cochrane.Author)
Figure 4.2: Number of Trials in the selected Cochrane
We used Stem and Leaf plot to demonstrate the distribution of the number of authors
and the trials in the reviewed studies from Cochrane and Non-Cochrane databases as shown
in Fig 4.2,4.3, 4.4 and 4.5 which display positive skewness. This is more prominent in the
non-Cochrane journals. The paper-base journal has the highest number of authors and trials
compared with Cochrane library.
45Figure 4.3: Number of Trials in the selected non-Cochrane studies
There were no statistically signicant dierence between the Cochrane Collaboration and
Paper-Base journal in most of the items except for item number 9 with p = 0.003. This item
showed that the paper based journals more often use the instrument developed by Oxman
et al (1988)[80] to assess the validity of included studies than the Cochrane Collaboration
based papers.
4.5.3 Methodological Quality
From our review, we found that both Cochrane and paper-base journals adequately reported
the objectives/hypothesis, described the main outcomes in the introduction and reported
comprehensive search methods. This nding may be indicative of the fact that most authors
follow the stipulations in existing checklists. This is an important development in that
reviewers can have a bird's eye view of a publication without having to go through the whole
publication. Thus, selection of eligible studies for inclusion in reviews is enhanced and faster
because decision for inclusion or otherwise can be reached by reading a well-detailed abstract.
46Figure 4.4: Number of Authors in the selected Cochrane
From our investigation, Cochrane is more likely (74%) to contact authors of unpublished
articles than paper-base journals (56%). Also the Cochrane groups are slightly more rigorous
42(100%) in stating steps taken to avoid selection bias compared with 38(93%) of the paper-
base journals.
We selected two checklists - Overview Quality Assessment Questionnaire (OQAQ) and
Quality Of Reporting Of Meta-analysis (QUOROM) which we included in our checklist
as guide for assessing the scientic quality, methodological quality and reporting quality.
Surprisingly, only 1(2.4%) study in Cochrane review explicitly stated the use of QUOROM
or OQAQ to assess quality against 10(24%) of paper-base journals that explicitly stated the
use of the checklists. The results showed a statistical signicant dierence with P = 0.003.
However, further investigation indicate that Cochrane library prefer the use of checklists
prepared by Cochrane Renal Group, Cochrane approach - Jadad scale (1996) and other
Cochrane Review checklists related to interventions under investigation.
47Figure 4.5: Number of Authors in the selected non-Cochrane studies
48Study design of a clinical trial could be parallel, crossover or factorial where participants
are randomized or blinded to given treatments over a period of time, and outcomes are mea-
sured. In meta-analysis, statistical techniques used to combine studies should be consistent
with the design. Thus, we advocate that meta-analysts should state the design of each study
included in analysis in order to prevent a mismatch of studies.
For instance in Cochrane review, the meta-analysis on tropical antibiotics without steroids
for chronically discharging ears by Macfadyne et al (2005 [81] reported the study designs of
individual trials included in the study. He had 14 trials - 13 parallel groups and 1 crossover
group. He went further to state that he used results of the rst period before participants
were crossed over to the alternative treatment. One other author combined several study
designs which includes parallel, crossover, comparative, prospective study and randomised
controlled trials. Nevertheless, from our assessment, Cochrane reviews were more likely 31%
than paper-base journal 17% to report the types of study designs that were combined in the
meta-analysis.
It was dicult to adequately assess items 14 and 15 of the checklist which has to do
with compatibility of combined studies given their individual design and if the statistical
method used in combining the studies is in harmony with the study design. This is because
of the failure of most authors to explicitly state the design of individual studies combined
in meta-analysis (item 13). There is need for authors to specify the design of individual
studies combined. The consequence of combining studies with dierent design background is
that interpretation of simple summaries becomes problematic. For instance, combining (a)
parallel study with crossover study, (b) prevalence study with incidence study, (c) double
with single blinded, (d) retrospective study with prospective study etc, may yield confusing
and misleading results.
The presence of statistical heterogeneity, clinical and methodological diversity could im-
pact on the compatibility of studies. Therefore, combining studies with dierent measured
49eects or studies with widely diering participants, interventions and outcomes may lead
to misleading conclusions. We have included the item on compatibility of studies into our
checklist to stimulate and provoke deep consideration of this all important issue among meta-
analysts. There is every need to reect on the design of individual studies being combined
and ensure that only compatible studies are used in the same meta-analysis.
Assessment of adequacy of statistical methods is easier when study designs are clearly
stated. Where information on study design is lacking, appraisal of appropriateness of statis-
tical method is hampered.
This checklist is designed with the aim of encouraging study authors to include as much
statistical information as is relevant in the published works. Rich statistical information
content of individual studies makes easy the work of the meta-analyst in the identication
and combination of compatible studies.
Given that our interest is to assess the quality of meta-analysis in terms of actual statis-
tical analysis, studies were reviewed to nd out whether the statistical methods used were
specied, whether the aim of using it was stated and if the use of the method was justi-
ed. Most authors that published their articles in Cochrane library mostly used statistical
methods such as odd ratio, relative risk and weighted mean deviation. In Cochrane 34(81%)
justied the methods used. In journals reviews, 98% reported the statistical methods used,
37(90%) stated the aim and 78% stated the justication of the methods used.
Sample size is the main factor in determining the weight for a trial. The larger the sample
size the more weight assigned and smaller the variance. Likewise, less weight is assigned to
the smaller sample size and with large variance. We identied that Cochrane reviews had
39(93%) that reported appropriate weight used to combine studies, 33(80%) reported in
journals with p=0.2
There is a need to report the actual probability values, rather than only saying that a
result is or is not statistically signicant, in this way the reader can compare the probability
50value to the signicance level[82]. We found that Cochrane reviews are more likely to state
the actual probability value and/or condence intervals in their analyses than journals.
We identied 40(95%) and 36(88%) studies in Cochrane and journal reviews respectively
that reported the actual probability values and/or condence interval in the meta-analysis.
However, most of these analyses (9 out of 10) used condence intervals and needed not state
the p-value.
Cochrane authors mostly used dierent versions of RevMan Statistical software in data
analysis. We noticed that paper-base journal did not only use RevMan statistical software
but also used other softwares like Statdirect, Statview, Micro strata and winBUGS. We
obtained 31(74%) studies reporting the use of statistical software in Cochrane and 27(66%)
in the journals.
Finally, we identied that the possibility of studies reviewed being reproduced by poten-
tial users is 95% and 93% in Cochrane database and journal database respectively. Also,
both databases made valid conclusions that was based on hypothesis test.
4.5.4 Double counting of some aspects of studies
There were no simple double counting of studies observed during the assessment in Cochrane
and Non-Cochrane databases, but we identied 4(10%) meta-analyses that contain double
counting of some aspects of studies in Cochrane reviews.
Here are the examples
Example 1: Figure 4.6 shows the evidence of double counting of some aspects of studies
identied in meta-analysis from Cochrane reviews. Saunder et al[83] in their meta-analysis
on the eect of physical tness training on dependency, death and disability after stroke,
included a trial published by Pohl [84] who included two separate treadmill training inter-
vention groups sharing the same control group. In this case, control arm was counted twice
51in the analysis of meta-analysis conducted by Sander et al.
Figure 4.6: Physical tness training for stroke patients by Sander et al(2004)
Example 2: Review published in Cochrane library is the meta-analysis by Rendon et al
[85]. He added the trial by Meluzin [86] with three-arm comparison, which had 22-patients
assessed in each arm. The two treatment arms were compared with the same control arm.
This led to double counting of control groups. This is shown in Figure 4.7.
Example3: Meta-analysis conducted by Urquahart et al [87] titled Antidepressants for
non-specic low back pain published in Cochrane library. Publication by Atkinson et al [88]
were added in meta-analysis. Atkinson et al compared Paroxetine (n=22) and Maprotiline
(n=20) drugs with the same active placebo (n= 32). The potential problem was that active
placebo was being counted more than once. Figure 4.8 represents the double counting of
some aspects of studies of Atkinson and his colleagues included in the meta-analysis by
52Figure 4.7: Stem cell treatment for acute myocardial infarction by Rendon et al(2008)
Urquahart et al.
Lastly, meta-analysis on Target-controlled infusion versus manually-controlled infusion of
propofol for general anaesthesia or sedation in adults by Leslie et al [89]. One of its included
studies named Struys et al [90] included two Manually-controlled infusion groups and one
Target-controlled infusion group. Two comparisons were made: TCI vs MCI1 and TCI vs
MCI2. This means that the placebo group was double counted. Figure 4.9 represents the
meta-analysis of Leslie et al [89].
There was no double counting of some aspects of studies identied in Paper - Base
Journal but we noticed that in a article published in BMJ by Arrol et al [91] titled \Are
antibiotics eective for acute purulent rhinitis? Systematic review and Meta-Analysis of
placebo Controlled Randomised Trials" included the publication of Taylor et al [92] who
53Figure 4.8: Double counting of some aspects of studies of Atkinson et al(1999)
compared more than two arms which include two treatment arms and one placebo arm. He
included 188 patients (Amoxillim = 54 patients, Cotrimoxazole = 75 patients and placebo
= 59). What the authors did was to divide the placebo into two section and assigned 30 and
29 of placebo group to each treatment group for analysis, and this technique prevented the
control arm being counted twice .
We cite other examples of paper-based journal that escaped the problem of double count-
ing of some aspects of studies. The meta-analysis of comparisons of Traditional digital Block
and Single Subcutaneous Palmar Injection Block published in Journal of Hand Surgery by
Yin et al [93]. In this meta-analysis, they included study published by Hung et al [94]
who compared three block techniques - one treatment trial (transthecal) and two control
trials (traditional block and subcutaneous palmar block), in that case, treatment arm was
54Figure 4.9: Double counting of some aspects of studies of Struys et al (2008)
55divided into two comparison groups, transthecal versus traditional block and transthecal
versus subcutaneous palmar block.
Another example was \Eect of iron supplementation on mental and motor development
in children: systematic review of randomised controlled trials"by Sachdev et al published in
Public Health Nutrition journal. In this meta-analysis, there are some studies with two or
more iron intervention groups and a single control group , the authors divided equally the
sample size of the control group between the number of intervention groups while retaining
the same value for the change in outcome and its standard deviation [95]. This was done to
avoid multiple counting of control group.
4.6 DATA IMPUTATION
In the course of review, we came across studies that reported the imputation of data during
their statistical analysis as a result of missing data. Some authors of the unpublished data
/ missing data were contacted but there were no responses. The only alternative was to
impute the missing or unreported data. The studies include - in Cochrane review,
 (i) a review on Propofol for sedation during Colonoscopy by Singh et al [96] stated that
all studies where the standard deviation were not reported, was calculated from other
measures of variance using the methodology suggested by Cochrane collaboration.
 (ii) review on Fluoride mouth rinses for preventing dental caries in children and ado-
lescents by Marinho et al (2003) [97] narrated how the missing main outcome data was
handled, the standard deviation for caries increments was imputed through the linear
regression of log standard deviation on log mean caries increments.
 (iii) review on Non-steroidal anti-inammatory drugs (NSAIDs) for treating lateral
elbow pain in adults by Green et al [98] explained that where necessary standard
56deviation was imputed from the range by division by 4.
Moreover, in Paper-base journal- a meta-analysis on Eects of calcium supplementation
on bone density in healthy children:
 (i) meta-analysis of randomised controlled trials by Winzenberg et al(2006) [99] pub-
lished in Medline database, imputed endpoint using baseline plus change for the mean
and using standard deviation of the baseline data for the endpoint standard deviation
where data for the analysis were not available.
The imputation of standard deviation using condence intervals, standard errors and
P-value when they are reported in the same study gives direct estimates. However, imputing
standard deviation from studies within the same meta-analysis or from studies reported in
another meta-analysis was found to yield accurate estimates of standard deviation [100].
However, the use of this approach calls for a careful appraisal of the how closely distributed
the data from individual studies are to the study whose standard deviation is being imputed.
Range imputation is very easy to use but can only be used in studies where the maximum
and minimum responses are reported. It may not be a good approximation of the standard
deviation as it may under estimate the actual value of standard deviation.
The use of linear regression method for imputation tends to underestimate variability in
the data. Also, the method assumes linear relationship between the dependent and indepen-
dent variables. Hence linearity must be established for this method to be eective.
The imputation of the endpoint standard deviation with baseline standard deviation
could yield approximately good results when the scale of measurement, the duration and
degree of measurement errors are the same in both the baseline and endpoint. But when
this condition fails, misleading results could be obtained.
It is our submission that the problem and need for imputation can be minimized if study
authors are sensitized enough on the need to include as much statistical information in
57published individual studies. Item 16 in our checklist is intended to address this.
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ASSESSMENT OF PRECISION OF
REPORTED STUDIES
Analysis of data from epidemiological studies rely on the estimation of the odds ratio, relative
risks and their 95% condence interval which must be reported by the authors [2]. Before
incorporating studies in meta-analysis, it is expedient that authors must check the accuracy
of relative risks, condence intervals and odds ratios against the data source where available.
Peter Lee [2] developed a simple method for checking errors in relative risks, odds ratios
and condence intervals in meta-analysis which comprised of checks on calculated statistics
reported in published papers after obtaining data for each study. The checks include:
 Consistency of Odds Ratios and Condence Intervals in 2x2 table
 Internal consistency of OR and CI
 Minimum number of total subjects given the CI
 Minimum number of subjects in any two groups combined given the CIs
 Minimum number of subjects in any group combined given the CI
59 Minimum number of total diseased subjects
 Minimum number of diseased subjects in either exposure groups
Lee [2] used these methods to assess the computed statistics of several studies-(E.g, Wu-
Williams et al [101], Geng et al [102], Hackshaw et al [103] and found that some of the
reported estimates were wrongly calculated. In this thesis, we used the same Lee simple
methods to assess claims of precision of individual studies.
Senn [52] alerted in his article titled \Overstating the evidence"published in BMC, that
users should be aware of any potential problems in the summary of reported estimates
and more serious problems of double counting of studies, double counting of some aspects
of studies, imputing data, poor reporting, accepting implausible claims for the precision
of individual studies, etc. He advised that authors must constantly check analysed results
before publishing and suggested that important standard for judgement is CHECKABILITY
which will improve the eectiveness and validity of meta-analysis. He therefore designed a
tool for checkability consisting of ve points as are listed below
 Be vigilant about double counting
 Make results checkable
 Describe approaches to analysis in detail
 Judge the meta-analysis not the analyst
 Create a culture of correction
Weir and Senn [3] developed SAS MACRO versions 8.2 in June/August 2008 named
mapeterlee and mabinary SAS Macros which we used to carry out checks as suggested by
Lee [2]. We used these macros in this project to check accuracy of reported estimates.
605.1 SAS MACRO
According to Cohen (A tutorial on SAS macro language, AsrtZeneca)\SAS Macro language
is another language that rests on top of regular SAS code. It can make programme easier and
save repetition and tedious eort. It consists of macro variables, macro language statements,
regular SAS program statements and macro functions which are contained within %MACRO
and a %MEND. The %MACRO statement includes a name and the macro is called using
the macro's name preceded by a %"[104] .
Weir and Senn [3] developed dierent types of SAS macro program but in this project,
we will make use of mapeterlee.sas and mabinary.sas in conducting checks on published
estimates.
(a)Mapeterlee.sas macro was used to calculate the minimum number of total subjects
given condence intervals, the value that any two elements should be equal or greater than
and that which any one element should be equal or greater than. The dataset needed for
the use of this macro include study name and standard error. (b)Mabinary.sas macro was
used to check consistency of odds ratio or relative risks and condence intervals using raw
data of included studies. The input data for this macro consist of study name, treat-event,
control-event, number in the treatment group (Nt), and number in the control group (Nc).
To do this, we selected ten studies each from Cochrane database and Paper-based Jour-
nals. The dataset input needed to execute the checks consist of study name, the number of
patients that received treatment, number of subjects that received placebo, the total number
of subjects in treatment and placebo, the point estimates(OR/RR) and their 95 or 99 per-
cent Condence intervals. In this case, dierent methods were applied to eect error checks
on the estimated Odds ratio and Relative risk in a 2x2 table, where raw data are available.
Lee [2] checks are detailed in the following subsections:
615.1.1 Check 1: The consistency of Odds ratio/Relative risks and
Condence Interval given a 2 x 2 table
The rst check was performed to verify the reliability of Odds ratio or Relative risks and
Condence intervals in a 2x2 table where data are available. The cell frequencies in the 2x2
contingency table is represented by a= number of exposed cases, b = number of unexposed
cases, c = number of exposed control and d = number of unexposed control, the sketch of 2x2
table is shown in Table 5.1.
Exposed Unexposed Total
Cases a b a + b
Control c d c + d
Total a + c b + d a + b + c + d
Table 5.1: The Contigency Table
Equations (1) and (2) represent the estimation of Odds ratio and Relative risks respec-
tively using available datasets from the selected studies.
Odds ratio = ^ r = ad/bc |||||||||||||||||{(1)
Relative Risk = ^ r = a(b + d)=b(a + c) |||||||||||||- (2)
and the variance of ln^ r for both Odds ratio and Relative risks were estimated from
2x2 table as given in Equations (3) and (4), the variance estimates obtained were used to
calculate upper and lower condence limits of the OR / RR for each study using equation
(5). The results derived were used to check for discrepancies on the reported values of lower
and upper condence limits in the included studies.
OR : V ar(lnr) = V1= 1=a + 1=b + 1=c + 1=d ||||||||||||{(3)
RR : V ar(lnr) = V2= 1=a + 1=b   1=(a + c)   1=(b + d) ||||||||||(4)
ln^ rL ln^ ru= ln^ r 1:96
p
V ar ||||||||-(5)
625.1.2 Check 2: Internal consistency of OR/RR and CI
This method is used to check the internal consistency of Odds ratio and condence inter-
vals when the original data are not accessible. Error check was performed on evenness of
condence intervals and odds ratio/Relative risk using equation(6)
OR2/RR2 = r2 = ru rl |||||||||||||(6)
where ru and rl = Upper and Lower Condence Limits
5.1.3 Check 3: Minimum number of total subjects given the CI
in a case control study
Checks can also only be based on the minimum size of the study implied by condence inter-
val, when the lower and upper condence interval (ru and rL) are given, they are known to
be 3.92 for (95%) or 5.16 for (99%) standard errors apart on the logarithmic scale. Standard
error was calculated using Lee' method shown in equation (7) and results obtained were used
as input in Mapeterlee sas macro. Mapeterlee sas.macro input data consists of study name
and standard error with a maximum of eight characters at. Alternatively, checks on mini-
mum number of total subjects in the group for odds ratio can be performed using formular
(8). The check is based on fact that the total number of subjects in the study should be
greater than or equal to this value estimated using (8).
V1 = [ln(ru=rl)=3:92]2 = Q2=15:3664 |||||||||||(7)
StandardError =
p
variance
Where Q = ln(ru=rl)
N  16=V1 or N  245:86=Q2 |||||||||||{(8)
where V1 = 1=a + 1=b + 1=c + 1=d
N = total number of subjects in the study
635.1.4 Check 4: Minimum number of subjects in any two groups
combined given the CIs in a case control study
The addition of any two elements of the 2x2 contigency table should be greater than or equal
to this value, this implies that
V1  1
m + 1
n ||||||||||{(9)
where m and n are any two dierent elements of the 2x2 table.
therefore (m + n)  61:47=Q2 ||||||||||||||-(10)
where 61.47 is constant
5.1.5 Check 5: Minimum number of subjects in any group given
the CI in a case control study
Any one element of 2x2 table should be greater than or equal this value which implies that,
V1  1
m, where m is any element of the 2x2 table
then, m  15:3664=Q2 ||||||||||||||-(11)
5.1.6 Check 6: Minimum number of total diseased subjects in a
cohort study
Here, we concentrate on the number of diseased subjects in both exposed and unexposed
groups. These groups must be greater than or equal to this estimated value from equation
(14). Equation (2) can be rewritten as
V2 =
a(a+c)
c +
b(b+d)
d  61:47=Q2 |||||||||||{(12)
a + b > a +
bc(b+c)
d(a+c) >= 61:47C=Q2(a + c) |||||||||||||-(13)
a + b  61:47S=Q2 ||||||||||||||||||||||||{(14)
where S = c=(a+c), is survival rate in the group at higher risk, for a rare disease S  1
64and for a relatively common disease in the exposed group, for example S = 0:9
5.1.7 Check 7: Minimum number of diseased subjects in either
exposure group in a cohort study
Equation (11) will be applied where m is either a or b
5.1.8 Application of Peter Lee's Methods on selected studies
We used Peter Lee's [2] simple methods to assess the consistency of reported odd ratios,
relative risks, condence intervals and minimum numbers of subjects sizes both in exposure
and unexposed groups in some selected studies. Peter Lee's checks include simple direct
calculation of odds ratio and standard errors when all four frequencies for a four-fold table
are available. These lead to equalities that must be satised. However his checks also provide
inequalities that should be satised when the individual entries are not available but only
certain marginal totals. Obviously, where the checks using individual frequencies can be
done there is no point in doing the checks involving marginal totals since the marginal totals
are determined by the cell frequencies. However, in order to illustrate the method we decided
to perform these checks anyway. This gave a surprising result. There were some studies that
passed the the checks involving individual entries but not the checks using totals. The only
possible explanation is that not all of Lee's checks are correct. It seems that the inequalities
that he provides for analyses based on odds ratios are correct but that those based on relative
risk are not correct. We will discuss this point later in this chapter.
Data from individual studies included in published meta-analysis in Cochrane and Non-
Cochrane reviews which are used for these checks are given in the rst four columns (left
hand side) of Tables 5.2 - 5.21 below.
We selected ten studies of meta-analyses from Cochrane and Non-Cochrane databases
65respectively. These studies have information on Study names, treatment groups size, placebo
size and estimates of MH(OR/RR) with their 95 or 99% CI which we presented in tables
in sub-section 5.2.9. The tables contain two columns - the left-hand side contains reported
data and estimates from the authors of meta-analysis and the right-hand columns display
our results of estimated Standard Errors and results of Lee's checks.
5.1.9 The sparse events and the use of continuity correction factor
of (0.5)
Using Peter Lee's simple methods and mapeterlee.sas macro, we calculated estimates of odds
ratio, relative risks and CIs. Some calculated CIs and RR/OR dier from the reported CIs
and RR/OR and the data did not meet requirements of minimum number of subjects sizes
for given CI.
A close observation of the data in the individual studies indicate that one prominent factor
that contributed to the discrepancies between reported estimates and calculated estimates
is zero outcomes in either the treatment or control group or both. To bridge this gap, we
introduced a continuity correction factor to all studies that reported zero outcomes. That
is, we added continuity correction factor of 0.5 to each cell. Results obtained were more
ecient in terms of matching the reported estimates of eect size and of CIs. Our analysis
tend to suggest that studies that reported odds ratio are more likely to meet the minimum
subject size requirement than studies reporting relative risks.
We calculated standard errors of individual studies using data reported by the authors.
The SEs were used as input dataset in the mapeterlee.sas.macro.
We employed each of the formula stated above (see Checks (1),(2),(3),(4),(5),(6) and (7)
) to assess error in the published studies. Studies reporting estimates of RR or OR were
treated dierently using relevant formula designed for the method (see subsections 5.2.3 -
665.2.7). The results obtained from these formulas were used to verify consistency of statistical
estimates reported by the authors.
Abbreviated terms with their meaning
CI ||{ Condence intervals
RR/OR |{ Relative risks/Odds ratio
Nt/Nc |{ Total number of treatment/control group
(P) ||{ Pass
(F) ||{ Fail
SE ||{ Standard Error Check(1) - Consistency of Odds Ratios and Condence Intervals
with 2x2 table.
Check(2) - Internal consistency of OR and CI.
Check(3) - Minimum number of total subjects given the CI(TS).
Check(4) - Minimum number of subjects in any two groups combined given the Condence
intervals(Two ele).
Check(5) - Minimum number of subjects in any group combined given the CI(One-ele).
Check(6) - Minimum number of total diseased subjects(TDS).
Check(7) - Minimum number of diseased subjects in either exposure groups(DS).
5.1.10 Examples of procedures used for checking errors in re-
ported estimates
Example: A study by Augustine et al 2004 (see the study in the rst row of table 5.2)
published in Meta-analysis by Rabindranath et al [105] in Cochrane library is used here to
illustrate how the results presented in the right-hand side columns of Tables 5.2 - Tables
5.21 were obtained. The data as reported by the authors is given as
67Augustine 2004
n1 = 40, n2 = 40,
b = 28, d = n2   b , d = 12 Frequencies in four-fold table
Total subjects = 80
condence limits:-
LCL = 0:72 , UCL = 1:30
Relative Risks = 0:96 ,
Given the fact the authors reported relative risk, we shall use checks (1), (2) formula to
assess correctness of reported estimates.
(i) STANDARD ERRORS - it is estimated based on frquencies
SE =
p
V1
Where the variance of Relative risks based on frequencies is estimated by
V1 = 1=A + 1=B   1=(A + C)   1=(B + D)
V1 = 1=27 + 1=28   1=(27 + 13)   1=(28 + 12)
V1 = 1=27 + 1=28   1=40   1=40
V1 = 0:037 + 0:036   0:025   0:025
V1 = 0:023 ||||||||{(1)
Therefore, Standard error =
p
0:023 = 0:15
(ii) Check (1) - Consistency of Relative Risks and Condence Intervals with 2x2 table
Relative risks = A(B + D)=B(A + C)
RR = 27(28 + 12)=28(27 + 13)
68RR = 27(40)=28(40) = 1080=1120
RR = 0:96
The CI[LCL;UCL] is then approximated by noting that
substitute value of V1 = 0:023 from eqn (1) to eqn(2)
lnLCL;lnUCL = lnRR  1:96(
p
V1) ||||||||{(2)
lnLCL;lnUCL = ln(0:96)  1:96
p
(0:023)
lnLCL;lnUCL =  0:041  1:96  0:15
=  0:041  0:297
lnLCL = e 0:34 = 0:71
lnUCL = e0:256 = 1:30
Lower limit 95% = 0:71
Upper limit 95% =1:30
Hence, we assigned pass (p) to check(1) since our calculated RR ,lower and upper con-
dence limits agree with that reported by Augustine et al 2004.
(iii) Check (2)Internal consistency of RR and CIs.
The formula is
p
LCL  ULC = 0:96 = RR = 0:96
We assigned pass (p) to check(2) because of the consistency between Relative Risk and
CIs
695.1.11 Peter Lee's checks on Cochrane reviews
Rabindranath [105] meta-analysis (Reported) Lee's Check
Study treatment control M-H(RR), 95% SE TDS DS (1)(2)(6)(7)
Augustine 2004 27/40 28/40 0.96[0.72 , 1.30] 0.15 57.95 44.01 (p)(p)(f)(f)
Gasparovic 2003 37/52 31/52 1.19[0.90, 1.58] 0.14 55.98 48.52 (p)(p)(p)(f)
Mehta 2001 55/84 39/82 1.38[1.05, 1.81] 0.14 71.57 51.82 (p)(p)(p)(p)
Noble 2006 43/54 34/40 0.94[0.78, 1.13] 0.09 91.13 111.83 (p)(p)(f)(f)
Uehlinge 2005 33/70 28/55 0.93[0.65, 1.33] 0.18 63.39 29.98 (p)(p)(f)(p)
Vinsonneau 2006 118/176 126/184 0.98[0.85, 1.13] 0.073 249.86 189.53 (p)(p)(f)(f)
Total 476 453 1.03[0.92, 1.16]
Table 5.2: Meta-analysis by Rabindranath et al(2007)
Terplan[106] meta-analysis (Reported) Lee's Check
Study treat control MH (RR)95% CI SE TDS DS (1)(2)(6)(7)
Elk 1998 5/6 4/6 1.25[0.64 - 2.44] 0.34 5.72 8.58 (p)(p)(p)(f)
Haug 2004 26/30 28/33 1.02[0.84 - 1.25] 0.10 51.87 97.25 (p)(p)(p)(f)
Jones 2001 44/47 36/38 0.99[0.89 - 1.10] 0.05 87.43 342.40 (p)(p)(f)(f)
Mulins 2004 17/35 23/36 0.76[.50 - 1.16] 0.21 44.64 21.70 (p)(p)(f)(f)
O'Neil 1996 40/47 40/45 0.96[0.82 - 1.12] 0.08 94.18 158.08 (p)(p)(f)(f)
Silveman 2001 11/20 8/20 1.38[0.71 - 2.68] 0.34 15.68 24.78 (p)(p)(p)(p)
Svikis 1997 27/40 18/36 1.35[0.91 - 2.00] 0.20 32.22 8.71 (p)(p)(p)(p)
Total (95% CI) 224 214 1.02[0.92 - 1.13]
Table 5.3: Psychosocial interventions for pregnant women in outpatient illicit drug treatment
programs compared to other interventions by Terplan(2007)
70Alonso[107] Meta-analysis (Reported) Lee's Check
Study treatment control M-H(RR) SE TDS DS (1)(2)(6)(7)
Himmelfarb 46/72 35/81 1.48[1.09 - 2.00] 0.15 60.25 41.71 (p)(p)(p)(p)
Kurtal 1995 48/84 43/76 1.01[0.77 - 1.32] 0.14 90.68 52.89 (p)(p)(p)(f)
Micheal 1995 7/11 10/12 0.76[0.46 - 1.28] 0.26 21.34 14.67 (p)(p)(f)(f)
Romao 1999 12/20 16/24 0.90[0.57 - 1.42] 0.23 29.51 18.44 (p)(p)(f)(f)
Schi 1994 20/26 9/26 2.22[1.26 - 3.92] 0.29 11.01 11.93 (p)(p)(p)(p)
Valeri 1996 19/25 16/28 1.33[0.90 - 1.96] 0.20 24.35 25.37 (p)(p)(p)(f)
Woo 2002 21/23 17/20 1.07[0.86 - 1.34] 0.11 27.18 78.13 (p)(p)(p)(f)
Kurtal 1995 13/25 17/32 0.98[0.60 - 1.61] 0.25 30.28 15.77 (p)(p)(p)(p)
Subtotal 286 299 1.15[0.95 - 1.38]
Table 5.4: Biocompatible hemodialysis membranes for acute renal failure Alonso et al (2008)
Macfacdyne[81] Meta-analysis (Reported) Lee's Check
Study Group quinolone Control MH-RR 95% SE TDS DS (1)(2)(6)(7)
Tutkun 1995 3/24 14/20 0.18(0.06, 0.53) 0.56 11.33 3.24 (p)(p)(p)(p)
Van Hasselt 1997 3/14 7/40 1.22(0.37, 4.10) 0.61 8.35 2.66 (p)(p)(p)(p)
VH 1998 daily 9/32 12/36 0.84(0.41, 1.74) 0.37 21.15 7.35 (p)(p)(p)(p)
VH 1998 wkly 16/39 13/31 0.98(0.56, 1.71) 0.28 29.09 12.33 (p)(p)(p)(p)
Fradis 1997 10/19 8/18 1.18(0.61, 2.31) 0.34 16.42 8.67 (p)(p)(p)(p)
Kaygusuz 2002 4/20 6/20 0.67( 0.22, 2.01) 0.56 10.05 3.14 (p)(p)(p)(p)
Subtotal (95% CI) 148 165 0.76 (0.55, 1.04)
Table 5.5: Topical antibiotics without steroids for chronically discharging ears with underlying
eardrum perforations by Macfadyen et al (2005)
71Martin[108] Meta-analysis (Reported) Peter Lee Check
Study BMSC no BMSC MH(RR) 95% CI SE TDS DS (1)(2)(6)(7)
Kang 2006 0/25 2/25 0.20(0.01 - 3.97) 1.53 1.72 0.43 (p)(p)(p)(p)
Lunde 2006 11/50 11/50 1.00(0.48 - 2.09) 0.38 22.15 7.10 (p)(p)(p)(p)
Meluzin 2006a 2/22 1/20 1.82(0.18 - 18.55) 1.08 2.60 0.72 (p)(p)(p)(p)
Meluzin 2006b 4/22 1/20 3.64(0.44 - 29.87) 1.18 2.83 0.86 (p)(p)(p)(p)
Mayer 2006 10/28 9/28 1.11(0.53 - 2.31) 0.38 18.23 7.09 (p)(p)(p)(p)
Subtotal (95% ) 147 143 1.10[0.63 - 1.80]
Table 5.6: Stem cell treatment for acute myocardial infarction Martin-Rendo et al(2008)
McCallum [109] Meta-analysis (Reported) Peter Lee Check
Study Open Closed MH(RR), 95% CI SE TDS DS (1)(2)(6)(7)
Al-Hassan 90 5/42 8/40 0.60[0.21 - 1.67] 0.53 12.60 3.57 (p)(p)(p)(p)
Fzn 94 0/45 2/46 0.20[0.01 - 4.14] 1.55 1.66 0.41 (p)(p)(p)(p)
Gencosmaoglu 1/73 12/69 0.08[0.01 - 0.59] 1.04 3.65 0.92 (p)(p)(p)(p)
Hameed 01 1/20 2/23 0.58[0.06 - 5.88] 1.17 2.78 0.73 (p)(p)(p)(p)
Khawaja 01 0/23 0/23 0.0[0.0 - 0.0] 0 0 0 undened
Kronborg 85 4/32 14/67 0.60[0.21 - 1.67] 0.53 12.51 3.57 (p)(p)(p)(p)
Miocinovic 99 2/25 6/25 0.33[0.07 - 1.50] 0.78 6.02 1.64 (p)(p)(p)(p)
Mohammed 05 2/55 3/28 0.34[0.06 - 1.92] 0.88 4.93 1.28 (p)(p)(p)(p)
Sndenna 92 3/60 6/60 0.50[0.13 - 1.91] 0.69 8.086 2.13 (p)(p)(p)(p)
Subtotal 375 381 0.38[0.23 - 0.63]
Table 5.7: Healing by primary versus secondary intention after surgical treatment for pi-
lonidal sinus by McCallum (2007)
In Table 5.7, all the reported CIs and RR agree with calculated estimates using Lee's
simple method except khawaja et al that reported zero condence intervals.
72Villatoro[110] MA (Reported) Peter Lee Check
Study Treat control MH(OR), 95% CI SE TS TE OE (1)(2)(3)(4)(5)
Isenmann 3/41 4/35 0.61[0.13 - 2.94] 0.80 25.28 6.32 1.58 (p)(p)(p)(p)(p)
Nordback 2/25 5/33 0.49[0.09 - 2.75] 0.87 21.03 5.26 1.31 (p)(p)(p)(p)(p)
Pederzoli 1993 3/41 4/33 0.57[0.12 - 2.76] 0.80 25.01 6.25 1.56 (p)(p)(p)(p)(p)
Sainio 1995 1/30 7/30 0.11[0.01 - 0.99] 1.17 11.64 2.91 0.73 (p)(p)(p)(p)(p)
Schwarz 1997 0/13 2/13 0.17[0.01 - 3.92] 1.52 6.90 1.72 0.43 (p)(p)(p)(p)(p)
Total 150 144 0.37[0.17 - 0.83]
Table 5.8: Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in
acute pancreatitis by Villatoro et al (2006).SE-standard error,TS-total subjects,TE-two
elements,OE-one element
Leslie[89] (Reported) Lee's Check
Study treat control M-H(OR), 95% CI SE TS TE OE (1)(2)(3)(4)(5)
H-Smith 1999 9/49 7/49 1.35[0.46 - 3.97] 0.55 52.93 13.23 3.31 (p)(p)(p)(p)(p)
Lehmann 2002 0/20 1/20 0.32[0.01 - 8.26] 1.71 5.45 1.36 0.34 (p)(p)(p)(p)(p)
l-Goytia 2005 17/45 29/45 0.33[0.14 - 0.79] 0.44 82.11 20.53 5.13 (p)(p)(p)(p)(p)
Newson 1995 5/21 5/21 1.00[0.24 - 4.14] 0.73 30.32 7.58 1.89 (p)(p)(p)(p)(p)
Passot 2002 4/27 12/27 0.22[0.06 - 0.80] 0.66 36.64 9.16 2.29 (p)(p)(p)(p)(p)
Russell 1995 9/76 21/80 0.38[0.16 - 0.89] 0.44 83.49 20.87 5.22 (p)(p)(p)(p)(p)
Struys 1997 14/31 8/29 2.16[0.74 - 6.36] 0.55 53.13 13.28 3.32 (p)(p)(p)(p)(p)
Struys 1997 14/31 7/30 2.71[0.90 - 8.15] 0.56 50.64 12.66 3.17 (p)(p)(p)(p)(p)
Total 300 301 0.76[0.38 - 1.54]
Table 5.9: Target-controlled infusion versus manually-controlled infusion of propofol for
general anaesthesia or sedation in adults Leslie et al (2008).SE-standard error,TS-total
subjects,TE-two elements,OE-one element
.
73Ritcher[111] (Reported) Lee's Check
Study Rosigli control M-H(OR), 95% SE TS TE OE (1)(2)(3)(4)(5)
Hanefeld 07 18/200 4/207 5.02[1.67 - 15.10] 0.56 50.71 12.68 3.17 (p)(p)(p)(p(p))
Kahn 2006 205/1456 123/1441 1.76[1.39 - 2.22] 0.12 1121.6 280.4 70.1 (p)(p)(p)(p)(p)
Ko 2006 2/56 0/56 5.18[0.24 - 110.45] 1.56 6.54 1.64 0.41 (p)(p)(p)(p)(p)
Lebovitz 2001 18/169 3/158 6.16[1.78 - 21.34] 0.63 39.85 9.96 2.49 (p)(p)(p)(p)(p)
Philips 2001 13/187 3/173 4.23[1.19 - 15.12] 0.65 38.05 9.51 2.38 (p)(p)(p)(p)(p)
Raskin 2004 2/62 0/63 5.25[0.25 - 111.56] 1.56 6.61 1.65 0.41 (p)(p)(p)(p)(p)
Rosenstock 06 14/112 0/104 30.77[1.81 - 522.71] 1.44 7.66 1.92 0.48 (p)(p)(p)(p)(p)
Stocker 2007 8/45 0/47 21.53[1.20 - 385.19] 1.47 7.38 1.85 0.46 (p)(p)(p)(p)(p)
Sutton 2002 7/104 1/99 7.07[0.85 - 58.57] 1.08 13.72 3.43 0.86 (p)(p)(p)(p)(p)
Total 2391 2348 2.27[1.83 - 2.81]
Table 5.10: Rosiglitazone for type 2 diabetes mellitus by Ritcher et al (2007).SE-standard
error,TS-total subjects,TE-two elements,OE-one element
5.1.12 Peter Lee's checks on Paper-Based Journals
Only Devereaux et al [113] used 99% CIs in their analysis as they believe that it conveys
better their condence in the estimate of treatment eect given the fact that the statistical
signifcance of their analysis depends on the dierence of only a handful of the events due to
small sample size. Reported CIs of some of the included studies in Devereaux et al [113] and
Webster et al [114] are consistent with calculated CIs obtained using Peter Lee methods.
Table 5.12 and Table 5.13 show respectively, outcomes of our investigations for the two
studies.
74Poole[112] (Reported) Lee's Check
Study treat contr M-H(OR), 95% SE TS TE OE (1)(2)(3)(4)(5)
Allegra 111/171 89/181 1.91[1.25, 2.94] 0.22 336.12 84.03 21.01 (p)(p)(p)(p)(p)
Baboli 134/254 58/241 3.52[2.40, 5.18] 0.20 415.40 103.85 25.96 (p)(p)(p)(p)(p)
Boman 46/98 29/105 2.32[1.29, 4.15] 0.29 180.08 45.02 11.25 (p)(p)(p)(p)(p)
Borgia 7/10 4/7 2.92[0.44,19.23] 0.96 17.23 4.31 1.08 (p)(p)(p)(p)(p)
Castig 240/311 179/302 2.32[1.64, 3.30] 0.18 502.87 125.72 31.43 (p)(p)(p)(p)(p)
Cremon 8/21 0/20 25.9[1.4, 485.3] 1.49 7.14 1.78 0.45 (P)(P)(p)(p)(p)
Grass 76 18/35 11/34 2.21[0.83, 5.88] 0.49 64.14 16.04 4.01 (p)(p)(p)(p)(p)
Grass 94 25/42 14/41 2.84[1.16, 6.92] 0.46 77.08 19.27 4.82 (p)(p)(p)(p)(p)
Grillage 35/54 29/55 1.65[0.77, 3.57] 0.39 104.49 26.12 6.53 (p)(p)(p)(p)(p)
Hansen 36/59 34/70 1.66[0.82, 3.35] 0.36 124.12 31.03 7.76 (p)(p)(p)(p)(p)
Jackson 41/61 36/60 1.37[0.65, 2.87] 0.38 111.48 27.87 6.97 (p)(p)(p)(p)(p)
Malerba 28/44 24/47 1.68[0.72, 3.88] 0.43 86.66 21.67 5.42 (p)(p)(p)(p)(p)
McGavin 11/72 8/76 1.53[0.58, 4.06] 0.49 64.93 16.23 4.05 (p)(p)(p)(p)(p)
Meister 1986 37/90 34/91 1.17[0.64, 2.13] 0.31 170.05 42.51 10.63 (p)(p)(p)(p)(p)
Meister 1999 79/122 56/124 2.23[1.34, 3.73] 0.26 234.6 58.65 14.66 (p)(p)(p)(p)(p)
Moretti 26/63 13/61 2.59[1.18, 5.73] 0.40 98.46 24.6 6.15 (p)(p)(p)(p)(p)
Norwak 114/147 101/148 1.61[0.96, 2.70] 0.26 229.93 57.48 14.37 (p)(p)(p)(p)(p)
Olivieri 56/110 21/104 4.10[2.23, 7.52] 0.31 166.39 41.60 10.40 (p)(p)(p)(p)(p)
Pela 37/83 17/80 2.98[1.50, 5.94] 0.35 129.81 32.45 8.11 (p)(p)(p)(p)(p)
Rasmussen 28/44 24/47 1.68[0.72, 3.88] 0.43 86.67 21.67 5.42 (p)(p)(p)(p)(p)
Total(95%CI) 1891 1896 2.23[1.95, 2.56]
Table 5.11: Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease
by Poole et al (2006).SE-standard error,TS-total subjects,TE-two elements,OE-one element
75Devereaux[113] Meta-analysis (Reported) Lee's Checks
Study B blocker cont MH(RR) 99%CI SE TDS DS (1)(2)(6)(7)
Cucchiara 0/37 1/37 0.33[0.01, 21.46] 1.49 1.79 0.45 (p)(p)(p)(p)
Liu 0/16 1/14 0.29[0.00, 17.86] 0.39 0.9 0.22 (p)(p)(p)(p)
Magnusson 4/15 0/15 9.00[0.22, 375.21] 1.44 1.38 0.48 (p)(p)(p)(p)
Stone 10/89 0/39 9.33[0.23,374.09] 1.43 1.72 0.48 (p)(p)(p)(p)
Mackenzie 1/50 0/50 3.00[0.05, 195.17] 1.61 1.51 0.39 (p)(p)(p)(p)
Jackobson 5/49 1/49 5.00[0.31, 80.06] 1.08 3.10 0.86 (p)(p)(p)(p)
Davies 12/20 8/20 1.50[0.64, 3.50] 0.33 14.76 9.22 (p)(p)(p)(p)
Wallace 2/99 1/101 2.04[0.09, 46.84] 1.21 2.67 0.68 (p)(p)(p)(p)
Yang 53/246 19/250 2.83[1.48, 5.42] 0.25 49.59 15.80 (p)(p)(p)(p)
Total 621 575 2.27[1.36, 3.80]
Table 5.12: The eect of perioperative blocker treatment in patients having non-cardiac
surgery by Devereaux et al 2005
TDS=Minimum number of total diseased subjects, DS=Minimum number of diseased
subjects in either exposure groups
76Webster[114] Meta-analysis (Reported) Lee's Check
Study group treatment control MH(RR ) 95% SE TDS DS (1)(2)(6)(7)
Rao 99 0/14 0/21 undened
Yang 99 0/30 1/31 0.33(0.01, 7.87) 1.70 1.38 0.35 (p)(p)(p)(p)
Van Duji 02 1/11 0/12 3.25(0.15, 72.36) 1.58 1.46 0.40 (p)(p)(p)(p)
Wang 2000 0/25 2/32 0.25(0.01, 5.06) 1.59 6.90 1.73 (p)(p)(p)(p)
White 2000 0/52 5/50 0.09(0.005, 1.54) 2.13 1.87 0.47 (p)(p)(p)(p)
Miller 02 1/100 3/50 0.17(0.02. 1.56) 1.11 3.21 0.81 (p)(p)(p)(p)
Laskow 95 4/92 1/28 1.22(0.14-10.45) 1.10 3.16 0.83 (p)(p)(p)(p)
Shapiro 91 2/28 3/29 0.69(0.12-3.83) 0.88 4.76 1.28 (p)(p)(p)(p)
Johnson 8/148 3/75 1.35(0.37-4.95) 0.66 8.64 2.28 (p)(p)(p)(p)
Trompeter 02 6/103 13/93 0.42(0.17 - 1.05) 0.46 17.46 4.64 (p)(p)(p)(p)
Campos 02 12/84 9/80 1.27(0.57 - 2.85) 0.41 20.34 5.93 (p)(p)(p)(p)
Pirsch 1997 10/205 19/207 0.53(0.25 - 1.11) 0.38 26.31 6.92 (p)(p)(p)(p)
Margreiter 02 17/286 22/271 0.73(0.40 - 1.35) 0.31 39.078 10.39 (p)(p)(p)(p)
Mayer 1997 38/303 18/145 1.01(0.60 - 1.71) 0.27 49.01 14.01 (p)(p)(p)(p)
Subtotal (95% CI) 1481 1123 0.77(0.58 - 1.02)
Table 5.13: Individual datasets in Journal reviews by Webster et al(2005)
TDS=Minimum number of total diseased subjects, DS=Minimum number of diseased
subjects in either exposure groups
77Arroll[115] Meta-analysis (Reported) Lee's check
Study treat cont MH(RR) 95%CI SE TDS DS (1)(2)(6)(7)
Cederlof 20/26 14/25 1.37[0.92, 2.06] 0.21 21.83 23.65 (p)(p)(p)(f)
Dieppe 10/12 1/12 10.00[1.51, 66.43] 0.97 0.72 1.07 (p)(p)(p)(p)
Friedman 15/17 12/17 1.25[0.88, 1.78] 0.17 14.57 30.97 (p)(p)(p)(f)
Ganey 33/42 21/42 1.57[1.12, 2.21] 0.17 28.51 33.26 (p)(p)(p)(p)
Ravaud 16/25 7/28 2.56[1.26, 5.18] 0.36 11.07 7.69 (p)(p)(p)(p)
Smith 25/38 15/33 1.45[0.93, 2.24] 0.22 27.21 19.89 (p)(p)(p)(p)
Total(95% CI) 160 157 1.66[1.37, 2.01]
Table 5.14: Corticosteroid injections for osteoarthritis of the knee: meta-analysis, by Arroll
2004
Arroll[91] Meta-analysis (Reported) Lee's Check
Study Antibiotic placebeo MH(RR), 95%CI SE TDS DS (1)(2)(6)(7)
Taylor 1977a 72/75 25/30 1.15[0.98, 1.36] 0.084 22.89 143.10 (p)(p)(p)(f)
Taylor 1977b 51/54 25/30 1.13[0.95, 1.35] 0.09 27.66 124.44 (p)(p)(p)(f)
Todd 1984 6/26 9/24 0.62[0.26, 1.47] 0.44 15.76 5.12 (p)(p)(p)(p)
De Sutter 02 125/180 95/179 1.31[1.11, 1.55] 0.09 168.47 137.83 (p)(p)(p)(f)
Total (95% CI); 335 263 1.08[1.05, 1.33] 1.1873
Table 5.15: Meta-analysis of studies of outcomes of purulent rhinitis at ve to eight days by
Arroll 2006
5.1.13 The Estimation of Minimum number of subjects sizes
Lee [2] advocates that validity of reported Odds ratios/Relative risks and CIs can also be
checked where the original data are not available using some simple methods presented in
Check (3) - Check (7) above and the assessments were based on inequility approach. These
assumed the minimum total number of subjects in the study, the minimum total number of
diseased subjects in the study and the minimum number of subjects in any disease group
must be greater or equal to a calculated value using Lee's methods. All studies that met
the minimum number requirement were assigned (P)-Pass and (F)-fail if unable to met Lee's
criteria.
Checks (3),(4) and (5) are for assessment of point estimates(Odd ratios) of case control
studies corresponding to (i) Minimum number of total subjects given the CI - Check 3 (ii)
Minimum number in any two groups of subjects given CI -Check 4 and (iii) Minimum number
78Goldberg[116] Meta-analysis (Reported) Lee's Checks
Study treat cont MH(RR)95%CI SE TDS DS (1)(2)(6)(7)
Pizzo 5/18 3/16 1.48[0.42, 5.24] 0.64 6.97 2.41 (p)(p)(p)(p)
EORTIC 11/68 14/64 0.74[0.36, 1.51] 0.37 25.06 7.48 (p)(p)(p)(p)
Schiel 2/101 0/54 2.70[0.13, 55.17] 1.54 1.65 0.42 (p)(p)(p)(p)
Wingard 4/97 5/111 0.92[0.25, 3.31] 0.66 8.83 2.30 (p)(p)(p)(p)
Goldstone 1/64 1/69 1.08[0.07, 16.88] 1.40 2.01 0.51 (p)(p)(p)(p)
Cordonnier 3/150 7/143 0.41[0.11, 1.55] 0.67 8.61 2.20 (p)(p)(p)(p)
Total 498 457 0.82[0.50, 1.34]
Table 5.16: Empirical antifungal therapy for patients with neutropenia and persistent
fever:Meta-analysis by Goldberg et al 2008
Tan Fao[117] Meta-analysis (Reported) Lee's Check
Study Steroids placebo MH(OR) 95% se TS TE OE (1)(2)(3)(4)(5)
Cheng 8/85 13/43 0.24[0.09, 0.64] 0.50 63.89 15.97 3.99 (p)(p)(p)(p)(p)
Darmon 11/327 17/337 0.66[0.03, 1.42] 0.39 101.72 25.43 6.36 (p)(p)(p)(p)(p)
Francois 11/355 76/343 0.11[0.06, 0.22] 0.33 145.64 36.41 9.10 (p)(p)(p)(p)(p)
Gaussorgues 4/138 2/138 2.03[0.37, 11.27] 0.87 21.07 5.27 1.32 (p)(p)(p)(p)(p)
Ho 7/39 10/38 0.61[0.21, 1.82] 0.55 52.72 13.18 3.29 (p)(p)(p)(p)(p)
Lee 4/40 11/40 0.29[0.08, 1.02] 0.65 37.94 9.49 2.37 (p)(p)(p)(p)(p)
Total (95%) ` 45/984 129/939 0.30[0.15, 0.58]
Table 5.17: Prophylactic administration of parenteral steroids for preventing airway com-
plications after extubation in adults by Tan Fao et al(2008).SE-standard error,TS-total
subjects,TE-two elements,OE-one element
of subjects in any group combined given the CI - Check 5.
To obtain the estimate of Relative risks(RR) of a disease in relation to given exposure
there are two unique checks- checks (6) and (7) - which assess (i) Minimum number of total
diseased subjects (TDS) and (ii) Minimum number of diseased subjects in either group(DS).
As time permitted, we were able to carry out further checks on these individual studies
by assuming that the original data were not reported. Using Lee's simple methods stated in
subsection check(3)-check(7) , we used only reported CIs and Point estimates (RR/OR) of
each study. The results obtained as calculated minimum sizes were used to compare reported
OR/RR and CIs. We found consistency of estimates of OR while it seemed that most studies
reporting (RR) failed to meet Lee's requirements.
79Legg[118] MA (Reported) Lee's Checks
Study treat cont PETO(OR)95% SE TS TE OE (1)(2)(3)(4)(5)
Corr 33/55 32/54 1.03[0.48, 2.21] 0.39 105.45 26.36 6.59 (p)(p)(p)(p)(p)
Gilbertson 33/66 41/67 0.64[0.32, 1.26] 0.35 130.89 32.72 8.18 (p)(p)(p)(p)(p)
Drummond 2/42 3/23 0.32[0.05, 2.11] 0.95 17.55 4.39 1.09 (p)(p)(p)(p)(p)
Logan 6/52 14/58 0.42[0.16, 1.11] 0.49 65.53 16.38 4.09 (p)(p)(p)(p)(p)
Walker 18/90 27/86 0.55[0.28, 1.08] 0.34 134.92 33.73 8.43 (p)(p)(p)(p)(p)
Sackley 27/53 36/47 0.34[0.15, 0.76] 0.41 93.37 23.34 5.84 (p)(p)(p)(p)(p)
Parker 106/248 56/123 0.89[0.58, 1.38] 0.22 327.22 81.81 20.45 (p)(p)(p)(p)(p)
Total (95% CI) 607 458 0.67[0.51, 0.87]
Table 5.18: Eects of occupational therapy on personal activities of daily living by Legg et al
2007.SE-standard error,TS-total subjects,TE-two elements,OE-one element
Mohammed[119] Meta-analysis (Reported) Lee's Check
Study treatment cont MH(RR), 95%CI SE TDS DS (1)(2)(6)(7)
Mangat 1/16 2/17 0.53[0.05, 5.31] 1.19 2.65 0.71 (p)(p)(p)(p)
Nannini 1/19 1/16 0.84[0.06, 12.42] 1.36 2.048 0.54 (p)(p)(p)(p)
Hughes 12/28 17/24 0.61[0.37, 1.00] 0.25 35.53 15.54 (p)(p)(f)(p)
Kokturk 1/14 2/12 0.43[0.04, 4.16] 1.18 2.65 0.71 (p)(p)(p)(p)
Aggrarwai 9/50 10/50 0.90[0.40, 2.02] 0.41 19.22 5.86 (p)(p)(p)(p)
Drobina 2/60 1/50 1.67[0.16, 17.85] 1.20 2.67 0.69 (p)(p)(p)(p)
Mahajan 2/31 1/31 2.00[0.19, 20.93] 1.19 2.60 0.69 (p)(p)(p)(p)
Total 218 200 0.70[0.47, 1.04]
Table 5.19: Eect of nebulised magnesium sulphate upon hospital admission: systematic
review and meta-analysis by Mohammed et al(2007)
.
In the course of our investigation, we found that studies with large outcomes failed to
meet Lee's minimum subject size requiremrnets, especially where the eect size is reported as
relative risk. Hence, it seem that Lee [2] failed to consider the facts that when the outcomes
of events are large, their standard errors tend to be small. This small value of the variance is
the denominator in Lee's inequalities which divides a constant which is 61.47. The outcome of
this division is large values of estimated minimum totals. Also, large event outcomes implies
that the proportion surviving in the exposed (S = a/(a+c)) will be very small. As discussed
above the only logical explanation is that Lee's approach is generally inappropriate in studies
reporting relatives risks when the number of events is large compared to the number at risk.
Where this happens Lee's checks are often failed by studies even though the relative risk
80Barr[120] MA (Reported) Lee's Check
Study tiotr cont MH(OR), 95% SE TS TE OE (1)(2)(3)(4)(5)
Beeh 180/1236 80/403 0.69[0.51, 0.92] 0.15 706.39 176.59 44.15 (p)(p)(p)(p)(p)
Brusasco 129/402 156/400 0.74[0.55, 0.99] 0.15 711.63 177.91 44.48 (p)(p)(p)(p)(p)
Casaburi 198/550 156/371 0.78[0.59, 1.02] 0.14 820.40 205.10 51.28 (p)(p)(p)(p)(p)
Dusser 250/500 308/510 0.66[0.51, 0.84] 0.13 987.43 246.86 61.71 (p)(p)(p)(p)(p)
Niewoehner 255/914 296/915 0.81[0.66, 0.99] 0.10 1495.50 373.87 93.47 (p)(p)(p)(p)(p)
Verkindre 0/46 2/54 0.23[0.01, 4.83] 1.58 6.44 1.61 0.4023 (p)(p)(p)(p)(p)
Total(95% CI) 3648 2653 0.74[0.66, 0.83]
Table 5.20: Tiotropium for stable chronic obstructive pulmonary disease: meta-analysis by
Barr et al 2006.SE-standard error,TS-total subjects,TE-two elements,OE-one element
Chang[121] MA (Reported) Lee's Check
Study Treatment cont MH(OR), 95% SE TS TE OE (1)(2)(3)(4)(5)
Ours 7/8 9/9 0.26[0.01, 7.43] 1.69 5.63 1.41 0.35 (p)(p)(p)(p) (p)
Kijander 7/9 12/12 0.12[0.01, 2.86] 1.44 7.69 1.92 0.48 (p)(p)(p)(p)(p)
Ehere 2/5 4/6 0.33[0.03, 3.93] 1.24 10.34 2.59 0.65 (p)(p)(p)(p)(p)
Total (95%) 22 27 0.24[0.04, 1.27]
Table 5.21: Meta-analysis of Gastro-oesophageal reux interventions for chronic cough
associated with gastro-oesophageal reux by Chang et al(2006).SE-standard error,TS-total
subjects,TE-two elements,OE-one element
is calculated correctly. This seems to be a technical error. We recommend that further
investigation be carried out to establish what could be done to rectify this.
Table 5.22 presented below shows the results of the calculated minimum subjects sizes
listed at the right-hand column. We rst illustate how these checks were conducted using
Augustine et al 2004 published in Rabindranath et al
Example:- Augustine 2004 A = 27 B = 28 C = 13 D = 12 RR = 0:96 CI =
[0:72;1:30] se = 0:15 TDS = 57:95 TD = 44:01
(iv) Check (6) - Minimum number of total diseased subjects - (TDS)
A + B > A + (BC(B + D)=D(A + C))  61:47C=Q2(A + C)
More generally
A + B  61:47S=Q2
81Where S = C=(A + C) = 13=(13 + 27) = 13=40 = 0:33
Q = ln(ru=rl) = ln(1:30=0:72) = ln(1:81) = 0:59
Q2 = (0:59)2 = 0:35
therefore A + B  61:47S=Q2
A + B  61:47(0:33)=0:35 = 57:95
27 + 28 = 55 which is not greater than or equal to calculated TSD = 57:95 , hence, we
assigned fail (f) to check(6) .
Where TSD is the Minimum number of total diseased subjects(Check(6)).
(iv) Check (7)-Minimum number of diseased subjects in either exposure group
V1  1=z; where z is either A or B
z  15:3664=Q2
A or B 15:3664=0:35 = 44:0
A or B  44:0
where A = 27 or B = 28 is less than the calculated DS = 44:0, we assigned fail (f)
to check(7) Where DS is the Minimum number of diseased subjects in either exposure
group(Check (7))
Meta-analyses by Rabindranath et al 2007 [105] in Table 5.2, Terplan [106] in Table 5.3
and Alonso et al (2008) [107] in Table 5.4 published in Cochrane library and Arroll 2004
[115] in Table 5.14 and Arroll 2006 [91] in Table 5.15 published in Paper Journal show that
the total reported number of cases in both exposure groups and the number of cases in
82either exposure groups given condence intervals, were less than the results obtained for the
minimum total number of diseased subjects in the groups using formula in checks (6) and
(7). Studies reporting relative risks in both Paper-Base Journals and Cochrane reviews are
more likely to disagree with the Lee's requirement on minimum number of diseased subjects
in either exposure groups given the CI, than those repoting odd ratios. We also note that the
studies that did not meet the checks have very large outcomes, those with very few outcomes
scaled all the tests.
835.1.14 Mabinary.sas Checks on Reported CIs
Finally, dierent versions of SAS.macros developed by Weir and Senn [3] were employed to
check the reliability and validity of the reported estimates for all studies recorded by the
authors. Apart from using Mapeterlee.sas.macro, Mabinary.sas macro was also used to check
accuracy of reported estimates. Data input into the macro consists of study name ,treatment-
event, control-event, total number in the treatment and control groups, Methods e.g MH-RR,
MH-OR, Peto-OR etc and their 5% or 1% level of signicance. The results obtained using
these macros are consistent with those obtained using Peter Lee simple methods as shown
in Table 5.12 to Table 5.21 in the previous sections.
5.1.15 Summary of Result
(1)SUMMARY OF INDIVIDUAL STUDIES THAT PASS EACH OF THE CHECK
Results obtained by carrying out error checks using simple methods designed by Peter
Lee [2] on reported estimates of included individual studies in twenty selected meta-analyses,
ten each from Cochrane and Non-Cochrane reviews, are summarised in Table 5.23 and Table
5.24. The tables show the number (proportion) of included studies that passed each of the
checks as outlined in the previous subsections of this chapter. The checks were carried out
depending on whether the authors reported either odds ratios or relative risks. Table 5.23
reveals that Odds ratios reported in both Paper base journals and Cochrane reviews satised
all Lee's requirements . Reported condence intervals for Odd ratios and its corresponding
minimum number of subjects in any group are consistent with Lee's criteria in both Cochrane
reviews and Paper base journals. However, studies reporting relative risks in Paper-based
Journals are more likely to be consistent with Lee's criteria than those reporting relative risks
in Cochrane database when we consider the minimum number of diseased subjects sizes in
a given group as shown in Table 5.24. A possible explanation of this seemingly consistency
84of the Paper-based journals is that they tend to have smaller number of outcomes than that
of the cochrane reviews.
For reported relative risks, both Cochrane and Non-Cochrane reviews reported (100%)
condence intervals that were consistent with Lee's checks. Nevertheless, reported minimum
number of diseased subjects in either exposed groups for studies reporting relative risks,
seems to be more consistent in Paper based journals with about 91% of such studies meeting
Lee's criterion as against 63% of Cochrane libraries. Majority of studies published in the
Cochrane reviews are less likely to satisfy the Lee's requirements on check (6) and (7) com-
pared with the Paper-based Journals. We noted a general pattern among studies reporting
relative risk that failed the minimum subject requirements of Lee. These studies tend to
have very large event outcomes. Studies with smaller or rare event outcomes are more likely
to meet Lee's minimum subjects requirements
(2) SUMMARY OF INDIVIDUAL STUDIES THAT PASS ALL THE CHECKS
In Cochrane reviews, there were a total of eighty-three (83) individual studies contained
in the selected 10 meta-analyses and a total of Sixty-eight (68) individual studies in the
selected 10 Paper base meta-analyses. Table 5.25 was constructed to illustrate the number
of studies that passed all the Lee's checks in both Cochrane and Non-Cochrane reviews.
There were 67 (81%) out of 83 of included studies of meta-analysis in Cochrane reviews
that satised all the Lee's requirements compared to 60(88%) out of 68 studies of the Paper
base Journals. Conversely, about 19% and 12% of all included studies in Cochrane and
Paper base journals respectively, fall short of at least one of Lee's requirement. However, as
noted earlier, failure to meet Lee's minimum total requirements for studies reporting relative
risks does not imply that the reported estimates were wrong but that Lee's checks seems
inappropriate for such studies with large outcomes.
85Table 5.22: Estimation of Minimum number of subjects sizes
Rabindranath calculated Peter Lee Check
Study(RR) SE TDS DS (6)(7)
Augustine 2004 0.15 57.95 44.01 (f)(f)
Gasparovic 2003 0.14 55.98 48.52 (p)(f)
Mehta 2001 0.14 71.57 51.82 (p)(p)
Noble 2006 0.09 91.13 111.83 (f)(f)
Uehlinge 2005 0.18 63.39 29.98 (f)(p)
Vinsonneau 2006 0.073 249.86 189.53 (f)(f)
Terplan calculated Peter Lee Check
Study SE TDS DS (6)(7)
Elk 1998 0.34 5.72 8.58 (p)(f)
Haug 2004 0.10 51.87 97.25 (p)(f)
Jones 2001 0.05 87.43 342.40 (f)(f)
Mulins 2004 0.21 44.64 21.70 (f)(f)
O'Neil 1996 0.08 94.18 158.08 (f)(f)
Silveman 2001 0.34 15.68 24.78 (p)(p)
Svikis 1997 0.20 32.22 8.71 (p)(p)
Alonso's calculated Peter Lee Checks
Study SE TDS DS (6)(7)
Himmelfarb 0.15 60.25 41.71 (p)(p)
Kurtal 1995 0.14 90.68 52.89 (p)(f)
Micheal 1995 0.26 21.34 14.67 (f)(f)
Romao 1999 0.23 29.51 18.44 (f)(f)
Schi 1994 0.29 11.01 11.93 (p)(p)
Valeri 1996 0.20 24.35 25.37 (p)(f)
Woo 2002 0.11 27.18 78.13 (p)(f)
Kurtal 1995 0.25 30.28 15.77 (p)(p)
Arroll 2006 calculated Peter Lee Check
Study SE TDS DS (6)(7)
Taylor 1977a 0.084 22.89 143.10 (p)(f)
Taylor 1977b 0.09 27.66 124.44 (p)(f)
Todd 1984 0.44 15.76 5.12 (p)(p)
De Sutter 02 0.09 168.47 137.83 (p)(f)
Arroll 2004 calculated Peter Lee Check
Study SE TDS DS (6)(7)
Cederlof 0.21 21.83 23.65 (p)(f)
Dieppe 0.97 0.72 1.07 (p)(p)
Friedman 0.17 14.57 30.97 (p)(f)
Ganey 0.17 28.51 33.26 (p)(p)
Ravaud 0.36 11.07 7.69 (p)(p)
Smith 0.22 27.21 19.89 (p)(p)
86Table 5.23: Summary of Consistency of OR and RR and CIs with 2 2table
Checks(OR) No of Jou Rev No of Coch Rev
Check(1) 22(100%) 42(100%)
Check(2) 22(100%) 42(100%)
Total 22 42
Checks(RR) Journals Cochrane
Check(1) 46(100%) 41(100%)
Check(2) 46(100%) 41(100%)
Total 46 41
Table 5.24: Summary of Minimum number of subjects sizes without 22table
Checks(OR) No of Jou Rev No of Coch Rev
Check(3) 22(100%) 42(100%)
Check(4) 22(100%) 42(100%)
Check(5) 22(100%) 42(100%)
Total 22 42
Checks(RR) Journals Cochrane
Check(6) 44(96%) 31(75%)
Check(7) 42(91%) 26(63%)
Total 46 41
Table 5.25: No. of included studies that passed all the Lee's checks on reported estimates
Database Pass Fail Total
Journals 60(88%) 8(12%) 68
Cochrane 67(81%) 16(19%) 83
Total 126 25 151
87Chapter 6
DISCUSSION AND CONCLUSION
6.1 SUMMARY
This research work focus on developing a quality instrument to assess meta-analysis in terms
of actual statistical analysis. The history of meta-analysis was traced from 1976 when Glass
rst coined the term "meta-analysis". The use of meta-analysis can be traced to the 1960s
and has since then increased rapidly and widely as it serves its purpose in the healthcare
sector, government policy and decision making. The combination of individual trials to ob-
tain the statistical results and conclusions has lessened the huge search on medical literature
by clinicians who use it daily to interpret their interventions on patients' treatment. Three
types of meta-analysis were summarised by Senn [52] and its necessary steps for performance.
We obtained data for review from Cochrane and Non-Cochrane database. The objectives
/ aims of this research were to construct a checklist that would assess the quality of meta-
analysis in terms of statistical analysis and to measure its validity and reliability. We also
used Lee's methods to check errors on reported estimates.
Chapter 2 summarises the trend of checklist development from the 1960's and reviewed
guidelines published to aid preparation of a valid checklist. In our review, we listed eight
88instruments from 1996 till date that assessed quality of reporting, scientic quality and
methodological quality but could not obtain any that prepared checklist to assess statistical
quality. We also reviewed the use, benets and applications of checklists.
In Chapter 3, we developed a tool consisting of 24-items that was used to measure
eectively the quality of meta-analysis in terms of actual statistical analysis. The inclusion
criteria of the studies among others, include selecting meta-analysis published from 2000-
2008 in each database of Cochrane and Non-Cochrane.
We selected eligible studies that were published in English, full text and with search
strategy that is very comprehensive. Error bound for the estimation of sample size was
obtained and we established a sample size of 100, using the knowledge that variance of
proportion attains its maximum when is p=0.5 and estimated error bound to be 0.1.
The sample size (n=100) was distributed equally to Cochrane and Non-Cochrane database
where samples were selected using simple random sample conducted using R statistical pack-
age. Non-Cochrane database (Web of Knowledge and Medline) shared proportionally their
allocated sample size (n=50). Each selected simple random number was used to trace and
retrieve studies labelled with that number from the electronic database. We typed words
in the search topic as-"meta-analysis of randomised controlled trials" OR "metaanalysisran-
domised controlled trials " OR "meta analysis randomised controlled trials" published in
English, in full text and an article.
There were 515, 507 and 130 results in Cochrane, Web of Knowledge and Medline re-
spectively. During the assessment of quality of trials, some trials were excluded because
they did not meet the stated inclusion criteria. Therefore, eligible studies that were t for
task were 42, 31, 10 studies in Cochrane, Web of Knowledge and Medline respectively. The
two paper-base journals (Web of Knowledge and Medline) were merged to obtain a single
sample. Subsequently, pilot study was conducted to check the validity and practicability of
the constructed checklist.
89Chapter 4 emphasizes the analysis of data obtained from the quality assessment of se-
lected studies and results. Firstly, we evaluated the number of authors and number of trials
in each review. The number of trials in each meta-analysis ranges from 2 to 51, and that
of authors were between 2 and 20. Stem and leaf plot was constructed to determine their
distribution. The result showed positive skewness in the two groups, and the median number
of trials and authors are greater in the Cochrane than the paper-based journals.
We used the new checklist to assess quality of meta-analysis in terms of actual statistical
analysis in both Cochrane and Non-Cochran studies. In Table 4.2, the items which measure
the statistical quality of each study are (item 10) to (item 22). We calculated Fisher exact
test (two-sided) using SAS and R statistical packages to obtain the proportions and to
compare the responses to each item in the checklist. Results obtained in the pilot study
were consistent with that obtained when the checklist was modied. The results show that
there is no statistically signicant dierence between Cochrane and Non-Cochrane reviews in
most of the checklist items because most estimated p-values were greater than 0.05 except for
item nine(9) which is statistically signicant. This item suggest that paper-based journals
occasionally used OQAQ and QUOROM checklists to assess scientic and reporting quality
of their meta-analysis than Cochrane journals.
There were no simple double counting of studies found in the Cochrane and Paper-base
journal but we identied four examples of double counting of some aspects of studies in
meta-analysis published in Cochrane reviews (Sander et al [83], Rendon et al [85], Leslie et
al [89] and Urquahart et al [87]). These studies counted control arms more than once. One
Paper journal split control arms into equal half among the treatment groups (Arrol et al
2006 [91] and Yin et al [93]).
During the course of review of Cochrane library, we identied meta-analysis by (Marinho
et al [97] and Green et al [98] that imputed standard deviation as a result of missing data
and non-response from the authors when contacted. One meta-analysis did not include
90the imputed data in the analysis while the other imputed using linear regression of log of
standard deviation on log mean.
In chapter 5, the precisions of reported studies were assessed using mapeterlee SAS macro
version 8.2 and mabinary version 1.0. These SAS macro versions were developed by Weir
and Senn [3]. Mapeterlee sas macro requires input dataset of study name and standard
error while mabinary sas macro requires input dataset of study name, treatment-event, total
number in treatment groups, control-event and total number in control groups. Standard
error for each study was calculated using Peter Lee's method. Twenty studies (ten from each
database) were selected from Cochrane and Non-Cochrane databases.
Peter Lee's method was employed to check for errors in the reported estimates of relative
risks, odds ratios and condence intervals in the selected studies from Cochrane and Paper
journal reviews.
Some studies included in the meta-analysis reported zero adverse events either in the
treatment or control groups or both which led to a disparity between the calculated results
and the estimates reported by the authors. The addition of a continuity correction factor
of 0.5 to each cell of the studies with zero events took care of the disparities. Mabinary sas
macro was also used to assess and check the validity of reported odd ratios, relative risks
and condence intervals on both meta-analyses. The results obtained using the macros are
consistent with the original reported results in most studies.
Reported number of diseased subjects in either exposure groups for studies reporting
relative risks, seems to be more consistent in Paper based journals with about 91% of such
studies meeting Lee's criterion as against 75% of Cochrane libraries. Studies published in the
Cochrane reviews are less likely to satisfy the Lee's requirements on expected total number
of events and number of events in either exposure group (check (6) and (7)) compared with
the Paper-based Journals. We note however, that studies reporting relative risks which do
not comply with Lee's minimum subject number requirements are not wrong, but it does
91seem that Lee's checks are inappropriate or unliable for such studies with large outcomes.
Most of the studies that did not meet Lee's criteria have large events.
Also, studies reporting relative risks in both Paper-Base Journals and Cochrane reviews
are more likely to disagree with the Lee's requirement on minimum number of diseased
subjects in either exposure groups given the CI, than those repoting odd ratios. The reason
for this is as explained in the preceding paragraph. Studies reporting relative risks and have
large outcomes are more likely not to meet this requirement. this calls for caution in the use
of Lee's criteria for assessment of precision of such studies.
Overall, in Cochrane, there were a total of 83 individual studies included in the selected
10 meta-analyses of randomised controlled trials but only 67(81%) out the 83 individual
studies met all the Peter Lee's requirements . Also, for the Journal reviews, there were
a total of 68 individual datasets included in the selected 10 meta-analyses of randomised
controlled trials but only 60(88%) of them met all the requirements. All the studies that did
not meet Lee's criteria reported relative risks and have relatively large outcomes.
6.1.1 FURTHER WORK
For this checklist to be adopted as a valid tool for assessing the quality of meta-analysis, it
needs be validated by two or more professionals. This validation process of the checklist is left
as future work. Further investigation on the inability of Peter Lee's methods to adequately
cover the assessment of Relative Risks when the number of events is large compared to the
number at risk is recommended.
6.2 CONCLUSION
We have successfully developed a checklist instrument that is very unique in its content. It is
designed to assess not only the statistical quality of meta-analysis but also the reporting and
92scientic quality of meta-analysis. The checklist is designed not only for the meta-analyst
but also for study authors and review editors. Quality of statistical information provided
in the individual studies has direct relation on the quality of meta-analysis produced by
combining such studies. Study authors are encouraged by this instrument to include as
much statistical information as possible because information rich studies may yield high
quality review and meta-analysis if the information is appropriately utilized. Each item
of the instrument is intended to provoke deep consideration and reection on an aspect of
study aggregation. Items 1 to 9 of the checklist address the quality of review while items
10 to 24 deals with the actual statistical quality of studies and meta-analysis. For instance,
item ten reminds the reviewer to specify the statistical method used in combining studies.
Subsequent two items encourages the meta-analyst to think about the reason(s) for using the
stated method and to justify that such method is adequate or valid for such analysis. Validity
of statistical methods comes from its suitability with the data and being able to satisfy model
assumptions. Aggregation of studies requires a careful consideration of study compatibility
which is only determined from information on study design, participants, interventions,
methodology and outcomes. Where this information is missing, eective assessment of meta-
analysis combining such studies is hampered. Also, assessment of adequacy of statistical
methods used to analyse combined studies may not be possible. We advocate through the
items in the checklist that studies being combined have adequate information to enable
not only assessment of compatibility but also to minimize need for imputation. Double
counting of studies or some aspects of studies may distort results and conclusions from
meta-analysis. We have included these two items in the checklist to sensitize meta-analysts
on the need to look out for repeated studies and or arms of studies which may impact
on precision of estimates. Choice of weights used for combining studies is an important
element in study aggregation. This can make or mar the results of meta-analysis depending
on appropriateness or inappropriateness of weights. Also information on software used in
93analysis exposes its suitability or otherwise for such analysis. We strongly recommend the
routine use of this checklist by study authors, readers, editors and meta-analysts to identify
not only scientically sound but also statistically strong reviews. However, we accept that
a validation study is needed. This should be a collaborative project involving dierent
assessors and hence is not suitable for work leading to an MSc. We hope that our work
might encourage others to take this further.
We used the developed checklist to compare statistical quality of selected publications in
Cochrane and Non-Cochrane reviews. The results revealed no statistically signicant dier-
ence between the reporting and methodological quality of the Cochrane and non-Cochran in
most of the checklist items because most estimated p-values were greater than 0.05 (see Ta-
ble 4.2). The only exception is item (9) which indicates that the non-Cochrane reviews were
more likely to assess scientic and reporting quality using OQAQ and QUOROM checklists
than Cochrane reviews. Both reviews performed poorly in the explicit reportage of included
study designs making assessment of compatibility of combined studies dicult.
Double counting of some aspects of studies were found in Cochrane reviews. Analysis
suggests that studies reporting odd ratios are likely to be consistent with Lee's checks than
those reporting relative risks. We also showed that Peter Lee's checks involving large number
of events cannot be relied on to assess the quality of studies reporting relative risks.
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APPENDIX COCHRANE DATABASE
There were 515 meta-analyses and each was given a unique identication number from
1 to 515. The studies to be sampled were then identied using the following R code. Given
N = 515 records of Meta-analysis of RCT's which met the inclusion criteria and n = 50 is
121the sample size , then
> N <  515
> n <  50
> Identify <  c(1 : N)
> sort(sample(Identify;size = n;replace = F))
The list of simple random numbers for Cochrane is 27, 31, 32, 36, 40, 49, 62, 67, 76, 79, 81,
97, 103, 117, 119, 204, etc,
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,
N = 507 records of meta-analysis of RCT's that met inclusion criteria, n = 40 sample
papers
> N <  507
> n <  40
> Identify <  c(1 : N)
> sort(sample(Identify;size = n;replace = F))
The list of simple random numbers for WOK is 12, 19, 29, 63, 78, 110, 115, 125,142, 151,
175, 181 etc
MEDLINE
,
has N = 130 of meta-analysis of RCT's meeting the inclusion criteria, n = 39 sample
122papers
> N <  130
> n <  10
> Identify <  c(1 : N)
> sort(sample(Identify;size = n;replace = F))
The list of simple random numbers for Medline is 7, 8, 13, 23, 58, 79, 69, 90, 100, 123 etc
123